0000950170-24-123296 | 10-Q | XBRL Viewer

Property and Equipment

9 Months Ended

Sep. 30, 2024

Property Plant And Equipment [Abstract]

6. Property and Equipment

Property and equipment consisted of the following (dollars in thousands):


	Estimated Useful
	Life (Years)		September 30, 2024			December 31, 2023
Land		—	$	875		$	875
Buildings	39-40			17,389			17,389
Building improvements(1)	5-40			90,573			46,357
Machinery and equipment	3-15			65,733			60,410
Furniture, fixtures and office equipment	5-10			3,350			3,070
Computer equipment and software		3		8,811			8,658
Construction in progress(1)		—		5,242			48,997
Total property and equipment				191,973			185,756
Less accumulated depreciation				(106,634	)		(101,536	)
Total property and equipment, net			$	85,339		$	84,220

___________________________

(1)

During the nine months ended September 30, 2024, the Company transferred $43.5 million from construction in progress to building improvements for assets placed in service related to the expansion of the Company's manufacturing facility.

Depreciation expense related to property and equipment was as follows (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Depreciation Expense	$	2,099	$	1,117	$	5,151	$	3,250

During each of the three and nine months ended September 30, 2024, the Company retired $0.1 million of manufacturing equipment as it was no longer in service. The net book value for the disposed assets was de minimis. There were no asset retirements during the three and nine months ended September 30, 2023.

Commitments and Contingencies - Schedule of Financing Liability Lease Term and Discount Rate (Detail)	Sep. 30, 2024	Dec. 31, 2023
Commitments And Contingencies Disclosure [Abstract]
Weighted average remaining lease term (in years)	17 years 1 month 6 days	17 years 9 months 18 days

Commitments and Contingencies

9 Months Ended

Sep. 30, 2024

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

15. Commitments and Contingencies

Guarantees and Indemnifications — In the ordinary course of its business, the Company makes certain indemnities, commitments and guarantees under which it may be required to make payments in relation to certain transactions. The Company, as permitted under Delaware law and in accordance with its Bylaws, indemnifies its officers and directors for certain events or occurrences, subject to certain limits, while the officer or director is or was serving at the Company’s request in such capacity. The term of the indemnification period is for the officer’s or director’s lifetime. The maximum amount of potential future indemnification is unlimited; however, the Company has a director and officer insurance policy that may enable it to recover a portion of any future amounts paid. The Company believes the fair value of these indemnification agreements is minimal and therefore has not recorded any liability for these indemnities in the condensed consolidated balance sheets. The Company accrues for losses for any known contingent liability, including those that may arise from indemnification provisions, when future payment is probable and the amount can be reasonably estimated. No such losses have been recorded to date.

Litigation — The Company is subject to legal proceedings and claims which arise in the ordinary course of its business. The Company does not anticipate the final disposition of any matters will have a material adverse effect on the results of operations, financial position, or cash flows of the Company. The Company maintains liability insurance coverage to protect the Company’s assets from losses arising out of or involving activities associated with ongoing and normal business operations. The Company records a provision for a liability when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The Company’s policy is to accrue for legal expenses in connection with legal proceedings and claims as they are incurred.

Contingencies — Milestone Rights — In July 2013, the Company entered into the Milestone Rights Agreement with the Original Milestone Purchasers, pursuant to which the Company granted the Milestone Rights to receive payments up to $90.0 million upon the occurrence of specified strategic and sales milestones, $50.0 million of which remains payable to the Milestone Purchasers as of September 30, 2024. The Milestone Rights Agreement includes customary representations and warranties and covenants by the Company, including restrictions on transfers of intellectual property related to Afrezza. The Milestone Rights are subject to acceleration in the event the Company transfers its intellectual property related to Afrezza in violation of the terms of such agreement.

During each of the nine months ended September 30, 2024 and 2023, the Company made milestone payments of $5.0 million to the Milestone Purchasers. As of September 30, 2024 and December 31, 2023, the remaining Milestone Rights liability balance was $3.2 million and $3.9 million, respectively, and consisted of $0.7 million and $0.8 million, respectively, of current liability, which was presented as accrued expenses and other current liabilities, and $2.5 million and $3.1 million, respectively, of long-term liability, which was presented as milestone liabilities in the condensed consolidated balance sheets. The value of the Milestone Rights liability was based on initial fair value estimates calculated using the income approach and is reduced by milestone achievement payments made.

Loss Contingencies — Returns Reserve for Acquired Product — During the nine months ended September 30, 2024, the Company reassessed its previously-determined estimate for product returns associated with sales of V-Go that pre-date the Company's acquisition of the product and recorded an additional $1.4 million, which is included in accrued expenses and other current liabilities in the condensed consolidated balance sheets as of September 30, 2024 and being reduced as product returns are received. Losses on estimated returns of acquired product were recorded in general and administrative expenses in the condensed consolidated statements of operations.

Liability for Sale of Future Royalties — In December 2023, the Company executed a Purchase and Sale Agreement (the “PSA”) with Sagard Healthcare Partners Funding Borrower SPE 2, LP (“Sagard”). Pursuant to the PSA, Sagard paid the Company $150.0 million (the “Upfront Proceeds”), net of $0.4 million in reimbursements of Sagard’s fees and expenses (the “Reimbursements”), for the purchase of a 1% royalty on future net sales of Tyvaso DPI by UT under the terms of the UT License Agreement (the “Sagard Royalty”). Sagard will also pay the Company a milestone of $50.0 million if net sales of Tyvaso DPI meet or exceed $1.9 billion for any twelve consecutive months on or prior to December 31, 2026 (“Net Sales Threshold A”), or a milestone of $45.0 million if net Sales Threshold A is not met and net sales of Tyvaso DPI meet or exceed $2.3 billion for any twelve consecutive months on or prior to September 30, 2027 (“Net Sales Threshold B”), resulting in a purchase price not to exceed $200.0 million (the “Purchase Price”). If Net Sales Thresholds A and B are not met and net sales of Tyvaso DPI meet or exceed $3.5 billion for any calendar year after September 30, 2027, no royalties will be payable to Sagard for the remainder of that year. The PSA applies to net sales of Tyvaso DPI generated during October 1, 2023 through December 31, 2042 (the “Termination Date”) and will automatically terminate upon payment of the final royalty owed to Sagard thereafter. Upon the Termination Date, ownership of the Sagard Royalty will revert to the Company.

Given the Company’s continuing involvement with the generation of Tyvaso DPI revenue under the UT License Agreement and CSA, which includes the Company’s supply and manufacture of Tyvaso DPI, and the Company’s retention and associated defense and maintenance obligations of the intellectual property required in the manufacture of Tyvaso DPI, the Upfront Proceeds were recorded as a liability for sale of future royalties (the “Royalty Liability”) on the condensed consolidated balance sheets, and any proceeds from future milestones will be added to the Royalty Liability balance upon receipt. Although the Company is not obligated to repay any portion of the Purchase Price to Sagard, the Royalty Liability under the PSA is secured by a security interest granted to Sagard in the underlying 1% royalty rights and any proceeds therefrom. As a result of the PSA, transaction costs totaling $4.4 million (including the Reimbursements) are reported net of the Royalty Liability balance and amortized to interest expense in the condensed consolidated statements of operations over the life of the PSA using the effective interest method. Unamortized transaction costs totaled $4.2 million and $4.4 million at September 30, 2024 and December 31, 2023, respectively.

The Company will continue to recognize the full 10% of future royalty revenues in its condensed consolidated statements of operations, with the Sagard Royalty being non-cash revenue for the Company. As royalty payments are earned by and remitted to Sagard, the balance of the Royalty Liability will be effectively repaid as it is amortized over the life of the PSA. To amortize the Royalty Liability, the Company estimated the total amount of future royalty payments to be made to Sagard over the life of the PSA. The excess of those future estimated royalty payments over the Purchase Price proceeds received is recognized in the condensed consolidated statements of operations as non-cash interest expense over the life of the PSA utilizing an imputed effective interest rate. The effective interest rate is calculated based on the rate that would enable the debt to be repaid in full over the anticipated life of the arrangement. The interest rate may vary during the term of the agreement depending on a number of factors, including the amount and timing of forecasted royalty payments which affects the timing and ultimate amount of reductions to the liability. The Company will evaluate the effective interest rate periodically based on its forecasted royalty payments utilizing the prospective method.

The Company periodically assesses the forecasted royalty payments using a combination of historical results, internal projections and forecasts from external sources. To the extent such payments, or the timing of such payments, are materially different than original estimates, the Company will prospectively adjust the effective interest rate and amortization of the Royalty Liability.

The following table shows the activity within the Royalty Liability account during the nine months ended September 30, 2024 as well as the effective interest rate (dollars in thousands):


Balance, January 1, 2024	$	145,810
Amortization of deferred transaction costs		172
Non-cash interest expense on liability for sale of future royalties		12,548
Royalty revenue earned by or payable to Sagard		(9,635	)
Balance, September 30, 2024	$	148,895

Effective interest rate	8.8% – 11.5%

Sale-Leaseback Transaction— In November 2021, the Company sold certain land, building and improvements located in Danbury, CT (the "Property") to an affiliate of Creative Manufacturing Properties (the "Purchaser") for a sales price of $102.3 million, subject to terms and the conditions contained in a purchase and sale agreement.

Effective with the closing of the Sale-Leaseback Transaction, the Company and the Purchaser entered into a lease agreement (the “Lease”), pursuant to which the Company leased the Property from the Purchaser for an initial term of 20 years, with four renewal options of five years each. The total annual rent under the Lease starts at approximately $9.5 million per year, subject to a 50% rent abatement during the first year of the Lease, and will increase annually by (i) 2.5% in the second through fifth year of the Lease and (ii) 3% in the sixth and each subsequent year of the Lease, including any renewal term, utilizing a weighted average discount rate of 9.0%. The Company is responsible for payment of operating expenses, property taxes and insurance for the Property. The Purchaser will hold a security deposit of $2.0 million during the Lease term. Pursuant to the terms of the Lease, the Company has four options to repurchase the Property, in 2026, 2031, 2036 and 2041, for the greater of (i) $102.3 million and (ii) the fair market value of the Property.

Effective with the closing of the Sale-Leaseback Transaction, the Company and the Purchaser also entered into a right of first refusal agreement (the “ROFR”), pursuant to which the Company has a right to re-purchase the Property from the Purchaser in accordance with terms and conditions set forth in the ROFR. Specifically, if the Purchaser receives, and is willing to accept, a bona fide purchase offer for the Property from a third-party purchaser, the Company has certain rights of first refusal to purchase the Property on the same material terms as proposed in such bona fide purchase offer.

As of September 30, 2024, the related financing liability was $104.0 million, which was recognized in the condensed consolidated balance sheet and of which $94.0 million was long-term and $10.0 million was current. As of December 31, 2023, the related financing liability was $104.1 million, of which $94.3 million was long-term and $9.8 million was current.

Financing liability information was as follows (dollars in thousands):


	September 30, 2024		December 31, 2023
Weighted average remaining lease term (in years)		17.1		17.8


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Interest expense on financing liability	$	2,470	$	2,459	$	7,361	$	7,332

The Company's remaining financing liability payments were as follows (in thousands):


	September 30, 2024
Remainder of 2024	$	2,532
2025		10,269
2026		10,533
2027		10,849
2028		11,174
Thereafter		177,278
Total		222,635
Interest payments		(116,113	)
Debt issuance costs		(2,519	)
Total financing liability	$	104,003

Financing Lease — In May 2024, the Company acquired audio-visual equipment via a financing lease with de minimis monthly principal and interest payments and a termination date in May 2029.

Financing lease information was as follows (dollars in thousands):


	September 30, 2024
Financing lease right-of-use asset(1)	$	219

Financing lease liability-current(2)	$	52
Financing lease liability-long-term		171
Total	$	223

Weighted average remaining lease term (in years)		4.7
Weighted average discount rate		7.25	%

_________________________

(1)

Financing right-of-use asset is included in other assets in the condensed consolidated balance sheets.

(2)

Financing lease liability – current is included in accrued expenses and other current liabilities in the condensed consolidated balance sheets.

The Company's remaining financing lease payments were as follows (in thousands):


	September 30, 2024
Remainder of 2024	$	27
2025		54
2026		54
2027		54
2028		54
Thereafter		23
Total		266
Interest payments		(43	)
Total financing liability	$	223

Commitments — In July 2014, the Company entered into the Insulin Supply Agreement pursuant to which Amphastar manufactures for and supplies to the Company certain quantities of recombinant human insulin for use in Afrezza. Under the terms of the Insulin Supply Agreement, Amphastar is responsible for manufacturing the insulin in accordance with the Company’s specifications and agreed-upon quality standards.

In December 2023, the Company and Amphastar amended the Insulin Supply Agreement to extend the term, restructure the annual purchase commitments and include a capacity fee for certain future periods. The Company's remaining purchase commitments and estimated capacity fee liability as of September 30, 2024 were as follows (€ in millions):


	September 30, 2024
	Remaining Purchase Commitments		Estimated Capacity Fees
2025		—		1.5
2026(1)		4.2		2.0
2027		6.0		1.0
2028		6.0		1.0
2029		6.0		1.0
2030		6.0		1.0
2031		8.0		0.5
2032		8.0		0.5
2033		8.0		0.5
2034		4.4		0.5
Total		56.6		9.5

_________________________

(1)

If there is a delay in the availability of insulin with FDA approved inclusion bodies and supply does not begin in 2026 as currently expected, the Company will incur a capacity fee of €750,000 per quarter that the product is not available for purchase.

Pursuant to the amendment, the term of the Insulin Supply Agreement expires on the later of December 31, 2034 or until the completion of the total remaining purchase commitment quantities, unless terminated earlier, and can be renewed for additional, successive two-year terms upon 12 months’ written notice given prior to the end of the initial term or any additional two-year term. The Company and Amphastar each have normal and customary termination rights, including termination for a material breach that is not cured within a specific time frame or in the event of liquidation, bankruptcy or insolvency of the other party. In addition, the Company may terminate the Insulin Supply Agreement upon two years’ prior written notice to Amphastar without cause or upon 30 days’ prior written notice to Amphastar if a controlling regulatory authority withdraws approval for Afrezza, provided, however, in the event of a termination pursuant to either of the latter two scenarios, the provisions of the Insulin Supply Agreement require the Company to pay the full amount of all unpaid purchase commitments due over the initial term within 60 calendar days of the effective date of such termination.

The Company periodically reviews the terms of the long-term Insulin Supply Agreement and assesses the need for any accrual for estimated losses, such as lower-of-cost or net-realizable-value that will not be recovered by future product sales. The recognized loss on purchase commitments of $62.6 million and $64.8 million is included in our condensed consolidated balance sheets as of September 30, 2024 and December 31, 2023, respectively, and is reduced as inventory items are received or such liability is extinguished.

As a result of the increase in future cash flows for the excess capacity fees and extended term included in the amendment of the Insulin Supply Agreement, the Company analyzed the need for additional estimated losses and concluded that an increase in the recognized loss on purchase commitments was not required as the net realizable value of inventory resulting from the purchase commitment was in excess of the carrying value. Increases in costs associated with the amendment will be recognized through inventory as incurred.

Vehicle Leases — During the second quarter of 2018, the Company entered into a master lease agreement with Enterprise Fleet Management Inc. The monthly payment inclusive of maintenance fees, insurance and taxes is approximately $0.1 million. The lease expense is included in selling expenses in the condensed consolidated statements of operations.

Office Leases — In May 2017, the Company executed an office lease with Russell Ranch Road II LLC for the Company’s corporate offices in Westlake Village, California, which was renewed in April 2022. Pursuant to the renewal, the monthly lease payments of $79,543 began in February 2023 and are subject to 3% annual increases, plus the estimated cost of maintaining the property and common areas by the landlord, and are further subject to a six-month base rent concession beginning February 2023. The Company is also entitled to a one-time allowance up to $0.9 million as reimbursement for tenant improvements or the purchase of furniture,

fixtures or equipment. Of the $0.9 million allowance, an amount up to $0.7 million may be applied as an additional base rent concession. The Company has no further right to extend the lease term beyond July 31, 2028.

In May 2022, the Company assumed certain leased real property (the “Marlborough Lease”) in connection with the V-Go acquisition. The Marlborough Lease pertains to certain premises in a building located in Marlborough, Massachusetts. The monthly payments of $28,895 began in June 2022, subject to approximately 3% annual increases through February 28, 2026.

The Company also acquired rights to a manufacturing service agreement where V-Go is manufactured using Company-owned equipment located at the manufacturing facility. The Company determined that this arrangement results in an embedded lease which granted the Company exclusive use of space within the manufacturing facility. The Company assessed the embedded lease cost to be $14,370 per month through February 28, 2026.

In July 2024, the Company assumed certain leased real property (the "Bedford Lease") in connection with the Pulmatrix Transaction. The Bedford Lease pertains to certain premises in a building located in Bedford, Massachusetts. The monthly base rent payments of $101,282 are subject to 3% annual increases, plus the estimated cost of maintaining the property and common areas by the landlord. The Company also assumed from Pulmatrix a $0.7 million obligation to repay landlord-funded tenant improvements at a rate of $6,000 per month through the end of the lease term in November 2033. The Company has the right to extend the lease term for an additional five-year term.

Lease information was as follows (dollars in thousands):


	September 30, 2024			December 31, 2023
Operating lease right-of-use assets(1)	$	13,637		$	4,685

Operating lease liability-current(2)	$	2,431		$	1,423
Operating lease liability-long-term		12,167			3,925
Total	$	14,598		$	5,348

Weighted average remaining lease term (in years)		7.3			3.7
Weighted average discount rate		7.25	%		7.25	%

_________________________

(1)

Operating right-of-use assets related to vehicles, offices and the manufacturing facility for V-Go are included in other assets in the condensed consolidated balance sheets.

(2)

Operating lease liability – current is included in accrued expenses and other current liabilities in the condensed consolidated balance sheets.


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Operating lease costs	$	719	$	422	$	1,417	$	1,253
Variable lease costs		104		48		122		97
Cash paid		860		268		1,407		825

The Company's future minimum office and vehicle lease payments were as follows (in thousands):


	September 30, 2024
Remainder of 2024	$	784
2025		3,157
2026		2,579
2027		2,540
2028		2,087
Thereafter		7,721
Total		18,868
Interest expense		(4,270	)
Total operating lease liability	$	14,598

Property and Equipment, Net (Detail) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Property Plant And Equipment [Line Items]
Total property and equipment	$ 191,973	$ 185,756
Less accumulated depreciation	(106,634)	(101,536)
Total property and equipment, net	85,339	84,220
Land
Property Plant And Equipment [Line Items]
Total property and equipment	875	875
Buildings
Property Plant And Equipment [Line Items]
Total property and equipment	$ 17,389	17,389
Buildings \| Minimum
Property Plant And Equipment [Line Items]
Estimated Useful Life (Years)	39 years
Buildings \| Maximum
Property Plant And Equipment [Line Items]
Estimated Useful Life (Years)	40 years
Building Improvements
Property Plant And Equipment [Line Items]
Total property and equipment	$ 90,573	46,357
Building Improvements \| Minimum
Property Plant And Equipment [Line Items]
Estimated Useful Life (Years)	5 years
Building Improvements \| Maximum
Property Plant And Equipment [Line Items]
Estimated Useful Life (Years)	40 years
Machinery and Equipment
Property Plant And Equipment [Line Items]
Total property and equipment	$ 65,733	60,410
Machinery and Equipment \| Minimum
Property Plant And Equipment [Line Items]
Estimated Useful Life (Years)	3 years
Machinery and Equipment \| Maximum
Property Plant And Equipment [Line Items]
Estimated Useful Life (Years)	15 years
Furniture, fixtures and office equipment
Property Plant And Equipment [Line Items]
Total property and equipment	$ 3,350	3,070
Furniture, fixtures and office equipment \| Minimum
Property Plant And Equipment [Line Items]
Estimated Useful Life (Years)	5 years
Furniture, fixtures and office equipment \| Maximum
Property Plant And Equipment [Line Items]
Estimated Useful Life (Years)	10 years
Computer Equipment and Software
Property Plant And Equipment [Line Items]
Total property and equipment	$ 8,811	8,658
Estimated Useful Life (Years)	3 years
Construction in Progress
Property Plant And Equipment [Line Items]
Total property and equipment	$ 5,242	$ 48,997

Accrued Expenses and Other Current Liabilities (Detail) - USD ($)
$ in Thousands

Sep. 30, 2024

Dec. 31, 2023

Payables And Accruals [Abstract]

Salary and related expenses

$ 16,239

$ 19,506

Discounts and allowances for commercial product sales

9,869

9,541

Accrued interest

479

2,153

Deferred lease liability

2,483

1,423

Current portion of milestone rights liability

639

752

Returns reserve for acquired product

^[1]

1,468

601

Professional fees

563

979

State income tax liability

1,507

1,561

Other

4,139

5,520

Accrued expenses and other current liabilities

$ 37,386

$ 42,036

[1]	See Note 15 – Commitments and Contingencies under Loss Contingencies — Returns Reserve for Acquired Product.

Earnings Per Common Share - Potential Dilutive Securities Outstanding that are Considered Antidilutive (Parenthetical) (Detail)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
RSU
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Share delivery percentage in accordance with valuation assessment obtained	219.00%	205.00%	0.00%

Condensed Consolidated Statements of Stockholders' Deficit - USD ($) shares in Thousands, $ in Thousands	Total	Convertible Note Interest The Mann Group L L C	Convertible Note Principal and Interest The Mann Group L L C	Common Stock	Common Stock Convertible Note Interest The Mann Group L L C	Common Stock Convertible Note Principal and Interest The Mann Group L L C	Additional Paid-in Capital	Additional Paid-in Capital Convertible Note Interest The Mann Group L L C	Additional Paid-in Capital Convertible Note Principal and Interest The Mann Group L L C	Accumulated Other Comprehensive Income	Accumulated Deficit
Beginning Balance at Dec. 31, 2022	$ (250,538)			$ 2,638			$ 2,964,293				$ (3,217,469)
Beginning Balance (in shares) at Dec. 31, 2022				263,793
Issuance of common stock associated with at-the-market offering	1,199			$ 3			1,196
Issuance of common stock associated with at-the-market offering (in shares)				269
Issuance costs associated with at-the- market offering	(24)						(24)
Net issuance of common stock associated with stock options and restricted stock units	52			$ 2			50
Net issuance of common stock associated with stock options and restricted stock units (in shares)				206
Issuance of common stock pursuant to conversion notes		$ 55						$ 55
Issuance of common stock pursuant to conversion notes (in shares)					11
Stock-based compensation expense	3,655						3,655
Net Income (Loss)	(9,795)										(9,795)
Ending Balance at Mar. 31, 2023	(255,396)			$ 2,643			2,969,225				(3,227,264)
Ending Balance (in shares) at Mar. 31, 2023				264,279
Beginning Balance at Dec. 31, 2022	(250,538)			$ 2,638			2,964,293				(3,217,469)
Beginning Balance (in shares) at Dec. 31, 2022				263,793
Net Income (Loss)	(13,339)
Ending Balance at Sep. 30, 2023	(251,779)			$ 2,695			2,975,891			$ 443	(3,230,808)
Ending Balance (in shares) at Sep. 30, 2023				269,543
Beginning Balance at Mar. 31, 2023	(255,396)			$ 2,643			2,969,225				(3,227,264)
Beginning Balance (in shares) at Mar. 31, 2023				264,279
Issuance of common stock associated with at-the-market offering	1,583			$ 4			1,579
Issuance of common stock associated with at-the-market offering (in shares)				362
Issuance costs associated with at-the- market offering	(17)						(17)
Issuance of common stock from market price stock purchase plan	152						152
Issuance of common stock under Market Price Stock Purchase Plan (in shares)				36
Net issuance of common stock associated with stock options and restricted stock units	(8,544)			$ 32			(8,576)
Net issuance of common stock associated with stock options and restricted stock units (in shares)				3,279
Issuance of common stock pursuant to conversion notes		54						54
Issuance of common stock pursuant to conversion notes (in shares)					13
Stock-based compensation expense	5,580						5,580
Issuance of common stock under the employee stock purchase plan	923			$ 3			920
Issuance of common stock under the employee stock purchase plan (in shares)				266
Cumulative gain on available-for-sale securities	443									443
Net Income (Loss)	(5,265)										(5,265)
Ending Balance at Jun. 30, 2023	(260,487)			$ 2,682			2,968,917			443	(3,232,529)
Ending Balance (in shares) at Jun. 30, 2023				268,235
Issuance of common stock associated with at-the-market offering	4,105			$ 8			4,097
Issuance of common stock associated with at-the-market offering (in shares)				847
Issuance costs associated with at-the- market offering	(67)						(67)
Net issuance of common stock associated with stock options and restricted stock units	(1,708)			$ 4			(1,712)
Net issuance of common stock associated with stock options and restricted stock units (in shares)				448
Issuance of common stock pursuant to conversion notes		56			$ 1			55
Issuance of common stock pursuant to conversion notes (in shares)					13
Stock-based compensation expense	4,601						4,601
Net Income (Loss)	1,721										1,721
Ending Balance at Sep. 30, 2023	(251,779)			$ 2,695			2,975,891			443	(3,230,808)
Ending Balance (in shares) at Sep. 30, 2023				269,543
Beginning Balance at Dec. 31, 2023	(246,168)			$ 2,700			2,980,539				(3,229,407)
Beginning Balance (in shares) at Dec. 31, 2023				270,034
Issuance of common stock associated with at-the-market offering	1,361						1,361
Issuance of common stock associated with at-the-market offering (in shares)				416
Net issuance of common stock associated with stock options and restricted stock units	266			$ 3			263
Net issuance of common stock associated with stock options and restricted stock units (in shares)				337
Issuance of common stock pursuant to conversion notes		$ 56						$ 56
Issuance of common stock pursuant to conversion notes (in shares)					15
Stock-based compensation expense	3,885						3,885
Net Income (Loss)	10,630										10,630
Ending Balance at Mar. 31, 2024	(229,970)			$ 2,703			2,986,104				(3,218,777)
Ending Balance (in shares) at Mar. 31, 2024				270,802
Beginning Balance at Dec. 31, 2023	(246,168)			$ 2,700			2,980,539				(3,229,407)
Beginning Balance (in shares) at Dec. 31, 2023				270,034
Net Income (Loss)	20,166
Ending Balance at Sep. 30, 2024	(209,926)			$ 2,753			2,995,974			588	(3,209,241)
Ending Balance (in shares) at Sep. 30, 2024				275,775
Beginning Balance at Mar. 31, 2024	(229,970)			$ 2,703			2,986,104				(3,218,777)
Beginning Balance (in shares) at Mar. 31, 2024				270,802
Net issuance of common stock associated with stock options and restricted stock units	(4,933)			$ 19			(4,952)
Net issuance of common stock associated with stock options and restricted stock units (in shares)				1,855
Issuance of common stock pursuant to conversion notes			$ 3,750			$ 15			$ 3,735
Issuance of common stock pursuant to conversion notes (in shares)						1,500
Stock-based compensation expense	6,428						6,428
Issuance of common stock under the employee stock purchase plan	959			$ 3			956
Issuance of common stock under the employee stock purchase plan (in shares)				310
Net Income (Loss)	(2,014)										(2,014)
Ending Balance at Jun. 30, 2024	(225,780)			$ 2,740			2,992,271				(3,220,791)
Ending Balance (in shares) at Jun. 30, 2024				274,467
Net issuance of common stock associated with stock options and restricted stock units	(1,511)			$ 13			(1,524)
Net issuance of common stock associated with stock options and restricted stock units (in shares)				1,308
Stock-based compensation expense	5,227						5,227
Cumulative gain on available-for-sale securities	588									588
Net Income (Loss)	11,550										11,550
Ending Balance at Sep. 30, 2024	$ (209,926)			$ 2,753			$ 2,995,974			$ 588	$ (3,209,241)
Ending Balance (in shares) at Sep. 30, 2024				275,775

Common and Preferred Stock

9 Months Ended

Sep. 30, 2024

Equity [Abstract]

Common and Preferred Stock

12. Common and Preferred Stock

The Company is authorized to issue 800,000,000 shares of common stock, par value $0.01 per share, and 10,000,000 shares of undesignated preferred stock, par value $0.01 per share, issuable in one or more series as designated by the Company’s board of directors. No other class of capital stock is authorized. As of September 30, 2024 and December 31, 2023, 275,775,038 and 270,034,495 shares of common stock, respectively, were issued and outstanding and no shares of preferred stock were outstanding.

In February 2018, the Company entered into a controlled equity offering sales agreement (the “CF Sales Agreement”) with Cantor Fitzgerald & Co. (“Cantor Fitzgerald”), as sales agent, pursuant to which the Company may offer and sell, from time to time, through Cantor Fitzgerald, shares of the Company’s common stock having an aggregate offering price of up to $50.0 million or such other amount as may be permitted by the Sales Agreement. Under the Sales Agreement, Cantor Fitzgerald may sell shares by any method deemed to be an “at-the-market offering” as defined in Rule 415 under the Securities Act of 1933, as amended. There were no sales under the CF Sales Agreement during the nine months ended September 30, 2024. During the nine months ended September 30, 2023, the Company sold 1,478,090 shares of common stock at a weighted average purchase price of $4.66 per share for gross proceeds of approximately $6.9 million pursuant to the CF Sales Agreement.

During the nine months ended September 30, 2024, the Company received $1.4 million from the market price stock purchase plan ("MPSPP") for 416,099 shares of common stock. During the nine months ended September 30, 2023, the Company received $0.2 million from the MPSPP for 36,004 shares.

For shares of common stock issued pursuant to the Company's 2004 employee stock purchase plan ("ESPP"), see Note 14 – Stock-Based Compensation Expense.

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-6

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

+ Details

Property and Equipment, Net (Parenthetical) (Detail) $ in Millions	Sep. 30, 2024 USD ($)
UT Manufacturing Facility
Property Plant And Equipment [Line Items]
Amount transferred from construction in progress to building improvements	$ 43.5

Accrued Expenses and Other Current Liabilities (Tables)

9 Months Ended

Sep. 30, 2024

Payables And Accruals [Abstract]

Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities were comprised of the following (in thousands):


	September 30, 2024		December 31, 2023
Salary and related expenses	$	16,239	$	19,506
Discounts and allowances for commercial product sales		9,869		9,541
Accrued interest		479		2,153
Deferred lease liability		2,483		1,423
Current portion of milestone rights liability(1)		639		752
Returns reserve for acquired product(2)		1,468		601
Professional fees		563		979
State income tax liability		1,507		1,561
Other		4,139		5,520
Accrued expenses and other current liabilities	$	37,386	$	42,036

_________________________

(1)

See Note 15 – Commitments and Contingencies under Contingencies — Milestone Rights.

(2)

See Note 15 – Commitments and Contingencies under Loss Contingencies — Returns Reserve for Acquired Product.

Collaboration, Licensing and Other Arrangements - Schedule of Revenue from Collaborations and Services (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from collaborations and services	$ 70,079	$ 51,253	$ 208,728	$ 140,490
United Therapeutics Corporation
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from collaborations and services	50,314	33,289	149,346	86,546
United Therapeutics Corporation \| Commercial Supply
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from collaborations and services	23,231	12,800	73,673	34,897
United Therapeutics Corporation \| License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from collaborations and services		271	347	698
United Therapeutics Corporation \| Royalties Arrangement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from collaborations and services	27,083	20,218	75,326	50,951
Collaborations and services
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from collaborations and services	23,268	13,108	74,130	35,705
Collaborations and services \| License and Distribution Agreement \| Cipla Ltd
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from collaborations and services	37	37	110	110
Collaborations and services \| United Therapeutics Corporation \| Commercial Supply Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from collaborations and services	$ 23,231	12,800	73,673	34,897
Collaborations and services \| United Therapeutics Corporation \| License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from collaborations and services		$ 271	$ 347	$ 698

Borrowings - Senior Convertible Notes - Additional Information (Detail)		1 Months Ended	9 Months Ended
	Mar. 04, 2021 USD ($) d $ / shares	Aug. 31, 2019	Sep. 30, 2024 USD ($) d $ / shares	Dec. 31, 2023 USD ($) $ / shares	Mar. 31, 2021 USD ($)
Debt Instrument [Line Items]
Maturity date		Dec. 31, 2025
Common stock, par value \| $ / shares			$ 0.01	$ 0.01
Senior Convertible Notes
Debt Instrument [Line Items]
Principal amount			$ 230,000,000	$ 230,000,000
Maturity date			Mar. 01, 2026
Annual interest rate			2.50%
Common stock, par value \| $ / shares			$ 0.01
Number of trading days \| d	20		20
Consecutive trading days \| d	30		30
Conversion price percentage	130.00%		130.00%
Principal amount per share \| $ / shares	$ 1,000		$ 1,000
Measurement period percentage			98.00%
Conversion price \| $ / shares	$ 5.21		$ 5.21
Initial conversion price of premium percentage	30.00%
No of convertible shares	191.8281
Redemption period start date	Mar. 06, 2024
Redemption price percentage	100.00%
Sinking fund	$ 0
Debt instrument redemption description			The Company may redeem for cash all or any portion of the Senior convertible notes, at its option, on or after March 6, 2024 and prior to the 36th scheduled trading day immediately preceding the maturity date, if the last reported sale price of common stock has been at least 130% of the conversion price for the Senior convertible notes then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption at a redemption price equal to 100% of the principal amount of the Senior convertible notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. If the Company elects to redeem less than all of the outstanding Senior convertible notes, at least $75.0 million aggregate principal amount of Senior convertible notes must be outstanding and not subject to redemption as of the relevant redemption notice date. No sinking fund is provided for the Senior convertible notes.
Percentage of repurchase price	100.00%
Debt default, description			If certain bankruptcy and insolvency-related events of default involving the Company (and not just any of its significant subsidiaries) occur, 100% of the principal of and accrued and unpaid interest on the Senior convertible notes will automatically become due and payable. If an event of default with respect to the Senior convertible notes, other than certain bankruptcy and insolvency-related events of default involving the Company (and not just any of its significant subsidiaries), occurs and is continuing, the trustee, by notice to the Company, or the holders of at least 25% in principal amount of the outstanding Senior convertible notes by notice to the Company and the trustee, may, and the trustee at the request of such holders shall, declare 100% of the principal of and accrued and unpaid interest, if any, on all the Senior convertible notes to be due and payable. Notwithstanding the foregoing, the Indenture provides that, to the extent the Company so elects, the sole remedy for an event of default relating to certain failures by the Company to comply with certain reporting covenants in the Indenture will, for the first 365 days after the occurrence of such an event of default consist exclusively of the right to receive additional interest on the Senior convertible notes as set forth in the Indenture
Proceeds from offering after deducting initial purchasers discounts and commissions and estimated offering expenses payable	$ 222,700,000
Unamortized debt issuance cost			$ 2,100,000	$ 3,100,000
Senior Convertible Notes \| Minimum
Debt Instrument [Line Items]
Outstanding principal amount redeemed	$ 75,000,000.0
Senior Convertible Notes \| Private Placement
Debt Instrument [Line Items]
Principal amount					$ 230,000,000.0

Borrowings

9 Months Ended

Sep. 30, 2024

Debt Disclosure [Abstract]

Borrowings

9. Borrowings

Carrying amount of the Company's borrowings consisted of the following (in thousands):


	September 30, 2024		December 31, 2023
Senior convertible notes	$	227,941	$	226,851
MidCap credit facility		—		33,019
Mann Group convertible note		—		8,829
Total debt – net carrying amount	$	227,941	$	268,699

The following table provides a summary of the Company’s principal balance of debt and key terms:

         
        Amount Due

        Terms

         
        September 30, 2024

        December 31, 2023

        Annual Interest
   Rate

        Maturity Date

        Conversion Price

        Senior convertible notes

        $230.0 million

        $230.0 million

        2.50%

        March 2026

        $5.21 
per share

MidCap credit facility(1)

—

$33.3 million

one-month
SOFR
(1% floor)
plus 6.25%;
cap of 8.25%

August 2025

N/A

Mann Group convertible note(2)

—

$8.8 million

2.50%

December 2025

$2.50
per share

_________________________

(1)

Repaid on April 1, 2024.

(2)

Repaid on April 2, 2024.

The maturities of the Company’s borrowings as of September 30, 2024 are as follows (in thousands):


	Amounts
Remainder of 2024	$	—
2025		—
2026		230,000
Total principal payments		230,000
Debt issuance costs		(2,059	)
Total debt	$	227,941

Senior convertible notes – In March 2021, the Company issued $230.0 million aggregate principal amount of Senior convertible notes in a private offering. The Senior convertible notes were issued pursuant to an indenture, dated March 4, 2021 (the “Indenture”), between the Company and U.S. Bank National Association, as trustee.

The Senior convertible notes are general unsecured obligations of the Company and will mature on March 1, 2026, unless earlier converted, redeemed or repurchased by the Company. The Senior convertible notes will bear cash interest from March 4, 2021 at an annual rate of 2.50% payable semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2021. The Senior convertible notes are convertible at the option of the holders at any time prior to the close of business on the business day immediately preceding December 1, 2025, only under the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on June 30, 2021 (and only during such calendar quarter), if the last reported sale price of the Company’s common stock, par value $0.01 per share, for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price for the Senior convertible notes on each applicable trading day; (2) during the five business day period after any ten consecutive trading day period in which the trading price (as defined in the Indenture) per $1,000 principal amount of the Senior convertible notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the common stock and the conversion rate on each such trading day; (3) if the Company calls such Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date, but only with respect to the Senior convertible notes called (or deemed called) for redemption; or (4) upon the occurrence of specified corporate events as set forth in the Indenture. On or after December 1, 2025 until the close of business on the business day immediately preceding the maturity date, holders may convert all or any portion of their Notes at any time, regardless of the foregoing circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of common stock or a combination of cash and shares of common stock, at the Company’s election, in the manner and subject to the terms and conditions provided in the Indenture.

The initial conversion rate is 191.8281 shares of common stock per $1,000 principal amount of Notes (equivalent to an initial conversion price of approximately $5.21 per share of common stock). The initial conversion price of the Senior convertible notes represents a premium of approximately 30% to the last reported sale price of the common stock on the Nasdaq Global Market on March 1, 2021. The conversion rate for the Senior convertible notes is subject to adjustment under certain circumstances in accordance with the terms of the Indenture, but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date of the Senior convertible notes or if the Company delivers a notice of redemption in respect of the Senior convertible notes, the Company will, in certain circumstances, increase the conversion rate of the Senior convertible notes for a holder who elects to convert its Senior convertible notes in connection with such a corporate event or convert its Notes called for redemption during the related redemption period (as defined in the Indenture), as the case may be.

The Company may redeem for cash all or any portion of the Senior convertible notes, at its option, on or after March 6, 2024 and prior to the 36th scheduled trading day immediately preceding the maturity date, if the last reported sale price of common stock has been at least 130% of the conversion price for the Senior convertible notes then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption at a redemption price equal to 100% of the principal amount of the Senior convertible notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. If the Company elects to redeem less than all of the outstanding Senior convertible notes, at least $75.0 million aggregate principal amount of Senior convertible notes must be outstanding and not subject to redemption as of the relevant redemption notice date. No sinking fund is provided for the Senior convertible notes.

If the Company undergoes a fundamental change (as defined in the Indenture), then, subject to certain conditions and except as described in the Indenture, holders may require the Company to repurchase for cash all or any portion of their Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Senior convertible notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.

The Indenture includes customary covenants and sets forth certain events of default after which the Senior convertible notes may be declared immediately due and payable.

If certain bankruptcy and insolvency-related events of default involving the Company (and not just any of its significant subsidiaries) occur, 100% of the principal of and accrued and unpaid interest on the Senior convertible notes will automatically become due and payable. If an event of default with respect to the Senior convertible notes, other than certain bankruptcy and insolvency-related events of default involving the Company (and not just any of its significant subsidiaries), occurs and is continuing, the trustee, by notice to the Company, or the holders of at least 25% in principal amount of the outstanding Senior convertible notes by notice to the Company and the trustee, may, and the trustee at the request of such holders shall, declare 100% of the principal of and accrued and unpaid interest, if any, on all the Senior convertible notes to be due and payable. Notwithstanding the foregoing, the Indenture provides that, to the extent the Company so elects, the sole remedy for an event of default relating to certain failures by the Company to comply with certain reporting covenants in the Indenture will, for the first 365 days after the occurrence of such an event of default consist exclusively of the right to receive additional interest on the Senior convertible notes as set forth in the Indenture.

The Indenture provides that the Company shall not consolidate with or merge with or into, or sell, convey, transfer or lease all or substantially all of the consolidated properties and assets of the Company and its subsidiaries, taken as a whole, to, another person (other than any such sale, conveyance, transfer or lease to one or more of the Company’s direct or indirect wholly owned subsidiaries), unless: (i) the resulting, surviving or transferee person (if not the Company) is a corporation organized and existing under the laws of the United States of America, any State thereof or the District of Columbia, and such corporation (if not the Company) expressly assumes by supplemental indenture all of the Company’s obligations under the Senior convertible notes and the Indenture; and (ii) immediately after giving effect to such transaction, no default or event of default has occurred and is continuing under the Indenture.

The Company’s net proceeds from the March 2021 offering were approximately $222.7 million, after deducting the initial purchasers’ discounts and commissions and the estimated offering expenses payable by the Company. As of September 30, 2024 and December 31, 2023, the unamortized debt issuance cost was $2.1 million and $3.1 million, respectively.

MidCap credit facility — In August 2019, the Company entered into the MidCap credit facility and borrowed the first advance of $40.0 million (“Tranche 1”) in August 2019 and the second advance of $10.0 million (“Tranche 2”) in December 2020. In April 2021, $10.0 million was prepaid.

Tranche 1 and Tranche 2 accrued interest at an annual rate equal to the lesser of (i) 8.25% and (ii) the one-month Secured Overnight Financing Rate ("SOFR") (subject to a one-month SOFR floor of 1.00%) plus 6.25%. Interest on each term loan advance was due and payable monthly in arrears. Principal on each term loan advance under Tranche 1 and Tranche 2 was payable in 24 equal monthly installments that began September 1, 2023.

During the three months ended March 31, 2024, the Company made $5.0 million in principal payments on the MidCap credit facility. On April 1, 2024, the Company exercised its option to prepay in full all outstanding indebtedness, consisting of $28.3 million in principal and $0.2 million in accrued interest, and terminated all commitments and obligations under the MidCap credit facility that would have matured on August 1, 2025 in exchange for a payment of $31.6 million, including an exit fee of $2.8 million which is 7.00% of the initial Tranche 1 balance of $40.0 million, and a prepayment fee of $0.3 million which is 1.00% of principal prepaid. Additionally, unamortized debt discount and capitalized prepayment fees totaling $0.2 million were written off, resulting in a loss on extinguishment of debt of $3.3 million recognized in the condensed consolidated statements of operations. In connection with the repayment of outstanding indebtedness by the Company, all liens, mortgages and security interests in any assets or property securing the obligations under the MidCap credit facility were automatically terminated and released and the Company was automatically released from all guarantees.

Mann Group convertible note — In August 2019, the Company issued a $35.0 million note that was convertible into shares of the Company’s common stock at $2.50 per share (the “Mann Group convertible note”) as part of a restructuring of its then existing indebtedness to Mann Group.

The Mann Group convertible note accrued interest at the rate of 2.5% per year on the principal amount, payable quarterly in arrears on the first day of each calendar quarter, with a maturity date of December 31, 2025.

The principal and any accrued and unpaid interest under the Mann Group convertible note was convertible, at the option of Mann Group, at any time on or prior to the close of business on the business day immediately preceding the stated maturity date, into shares of the Company’s common stock at a conversion rate of 400 shares per $1,000 of principal and/or accrued and unpaid interest, which is equal to a conversion price of $2.50 per share. Interest on the convertible note was payable in kind by adding the amount thereof to the principal amount; provided that with respect to interest accruing from and after January 1, 2021, the Company had the option to pay any such interest on any interest payment date, if certain conditions were met, in shares of the Company’s common stock at a price per share equal to the last reported sale price on the trading day immediately prior to the payment date.

During the nine months ended September 30, 2024, Mann Group converted $0.1 million of interest into 15,285 shares of common stock. During the nine months ended September 30, 2023, Mann Group converted $0.2 million of interest into 37,122 shares of common stock.

On April 2, 2024, the Company and Mann Group agreed to discharge and terminate the Mann Group convertible note. As of April 2, 2024, the outstanding principal balance of the Mann Group convertible note plus accrued interest was $8.9 million and was convertible at Mann Group’s option into 3,554,198 shares of common stock of the Company. The Company and Mann Group agreed to terminate all outstanding indebtedness, rights and obligations under the Mann Group convertible note in exchange for (i) the Company’s issuance to Mann Group of 1,500,000 shares of the Company’s common stock converted at the contractual rate of $2.50 per share and (ii) the Company’s payment to Mann Group of $8.9 million, which represented the market value of 2,054,198 shares of common stock of the Company on April 2, 2024 to settle the remaining principal and interest of $5.1 million, after the conversion noted in (i) above. Termination of the Mann Group convertible note resulted in a loss on extinguishment of debt of $3.7 million recognized in the condensed consolidated statements of operations.

Amortization of the premium and accretion of debt issuance costs related to all borrowings were as follows (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Amortization of debt discount and prepayment fee	$	—	$	109	$	85	$	323
Amortization of debt issuance cost		363		363		1,175		1,090

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 470
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/470/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

+ Details

Description of Business and Significant Accounting Policies - Additional Information (Detail) € in Millions, $ in Millions		1 Months Ended			9 Months Ended
	Jun. 27, 2024	Dec. 31, 2023 USD ($)	Jan. 31, 2022 USD ($)	Jun. 30, 2021 USD ($)	Sep. 30, 2024 EUR (€) Segment	Sep. 30, 2024 USD ($)	Jun. 30, 2024 USD ($)	Jul. 01, 2013 USD ($)
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Percentage of future royalties					1.00%
Number of operating segment \| Segment					1
Loss on purchase commitments \| €					€ 56.6
Sagard
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Percentage of royalty on net sales					1.00%
Percentage of royalty on future net sales		1.00%
Insulin
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Loss on purchase commitments		$ 64.8				$ 62.6
Tyvaso DPI
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Percentage of royalty on net sales					10.00%
Percentage of royalty on future net sales					9.00%
Percentage of royalty on net revenue					10.00%
Percentage of future royalties					9.00%
Maximum \| AFREZZA product sales
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Sales return right following product expiration in months					12 months
Minimum \| AFREZZA product sales
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Sales return right following product expiration in months					6 months
Convertible Promissory Note \| Thirona Bio, Inc.
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Increased interest rate	10.00%
Principal amount						$ 8.0	$ 8.0
Purchase of available-for-sale securities			$ 5.0	$ 3.0
Interest rate				6.00%
MidCap Credit Facility
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Principal amount		$ 33.3
Milestone Rights Liability \| Deerfield
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Contingent liability remain payable								$ 50.0
Milestone Rights Liability \| Maximum \| Deerfield
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Contingent liability for milestone payments								$ 90.0

Borrowings - MidCap Credit Facility - Additional Information (Detail) $ in Thousands		1 Months Ended			3 Months Ended	9 Months Ended	12 Months Ended
	Apr. 01, 2024 USD ($)	Apr. 30, 2021 USD ($)	Dec. 31, 2020 Installment	Aug. 31, 2019 USD ($) Installment	Mar. 31, 2024 USD ($)	Sep. 30, 2024 USD ($)	Dec. 31, 2020 USD ($)
Debt Instrument [Line Items]
Maturity date				Dec. 31, 2025
Debt instrument payment term description						Principal on each term loan advance under Tranche 1 and Tranche 2 was payable in 24 equal monthly installments that began September 1, 2023.
Loss on extinguishment of debt						$ (7,050)
MidCap Credit Facility
Debt Instrument [Line Items]
Prepaid of borrowing		$ 10,000
Debt Instrument unamortized prepayment penalty.	$ 200
Debt Instrument, Repaid, Principal	28,300
Accrued Interest	200
Principal payment on MidCap credit facility					$ 5,000
Payment of credit facility exit fee	2,800
Payment of credit facility prepayment fee	300
Loss on extinguishment of debt	3,300
Repayment of debt	$ 31,600
Early termination fees, percentage	1.00%
MidCap Credit Facility \| SOFR
Debt Instrument [Line Items]
Interest rate floor						1.00%
Tranche 1
Debt Instrument [Line Items]
Annual interest rate				8.25%
Debt payable number of equal monthly installments \| Installment				24
Line of credit facility principal payment start date				Sep. 01, 2023
Tranche 1 \| SOFR
Debt Instrument [Line Items]
Interest rate (LIBOR)				6.25%
Interest rate floor				1.00%
Tranche 1 \| MidCap Credit Facility
Debt Instrument [Line Items]
Advance of borrowing				$ 40,000
Debt instrument, prepayment penalty percentage	7.00%
Debt instrument, prepayment penalty	$ 40,000
Tranche 2
Debt Instrument [Line Items]
Annual interest rate			8.25%				8.25%
Debt payable number of equal monthly installments \| Installment			24
Line of credit facility principal payment start date			Sep. 01, 2023
Tranche 2 \| SOFR
Debt Instrument [Line Items]
Interest rate (LIBOR)			6.25%
Interest rate floor			1.00%
Tranche 2 \| MidCap Credit Facility
Debt Instrument [Line Items]
Advance of borrowing							$ 10,000

Inventories

9 Months Ended

Sep. 30, 2024

Inventory Disclosure [Abstract]

Inventories

5. Inventories

Inventories consist of the following (in thousands):


	September 30, 2024		December 31, 2023
Raw materials	$	6,437	$	6,262
Work-in-process		9,074		13,646
Finished goods		11,152		8,637
Total inventory	$	26,663	$	28,545

Work-in-process and finished goods as of September 30, 2024 and December 31, 2023 include conversion costs and exclude the cost of insulin. All insulin inventory on hand was written off and the projected loss on the purchase commitment contract to purchase future insulin was accrued as of the end of 2016. Raw materials inventory included $0.8 million of pre-launch inventory as of September 30, 2024 and December 31, 2023.

The Company analyzed its inventory levels to identify inventory that may expire or has a cost basis in excess of its estimated realizable value. The Company also performed an assessment of projected sales and evaluated the lower of cost or net realizable value and the potential excess inventory on hand as of September 30, 2024 and December 31, 2023. Inventory that did not meet acceptable standards or was forecasted to become obsolete due to expiration is reserved for inventory obsolescence in the condensed consolidated balance sheets and recorded in costs of goods sold in the condensed consolidated statements of operations. As a result of these assessments there were inventory write-offs of $0.3 million and $1.9 million for the three and nine months ended September 30, 2024, respectively, and $0.3 million and $3.7 million for the three and nine months ended September 30, 2023, respectively.

Inventories - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Inventory [Line Items]
Inventory write-offs	$ 300	$ 300	$ 1,909	$ 3,659
Pre-launch Inventory
Inventory [Line Items]
Raw materials inventory	$ 800		$ 800		$ 800

Accounts Receivable (Tables)

9 Months Ended

Sep. 30, 2024

Receivables [Abstract]

Schedule of Accounts Receivable, Net

Accounts receivable, net consists of the following (in thousands):


	September 30, 2024			December 31, 2023
Accounts receivable – commercial
Accounts receivable, gross	$	18,359		$	20,199
Wholesaler distribution fees and prompt pay discounts		(2,363	)		(2,469	)
Reserve for returns		(7,817	)		(6,215	)
Allowance for credit losses		—			(157	)
Total accounts receivable – commercial, net		8,179			11,358
Accounts receivable – collaborations and services		10,005			3,543
Total accounts receivable, net	$	18,184		$	14,901

Description of Business and Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2024

Accounting Policies [Abstract]

Summary of Revenue and Cost of Revenue and Goods Sold Generated From Product Sales, Services and Royalties

The Company’s net revenue and cost of revenue and goods sold as shown on the condensed consolidated statement of operations is comprised of revenue generated from product sales, services and royalties as shown below (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Net revenue:
Product revenue (1)	$	42,959	$	30,727	$	132,945	$	88,731
Services (2)		37		308		457		808
Royalties (3)		27,083		20,218		75,326		50,951
Total net revenue	$	70,079	$	51,253	$	208,728	$	140,490

_________________________

(1)

Amounts represent the revenue from Afrezza and V-Go sales to wholesalers and specialty pharmacies and Tyvaso DPI to UT.

(2)

Amounts represent revenue generated from the Company's collaboration arrangements, including Next-Gen R&D Services (as defined in Note 10) for UT as well as arrangements with other collaboration partners. See Note 10 – Collaboration, Licensing and Other Arrangements.

(3)

Amounts represent royalties on UT’s net revenue from Tyvaso DPI sales.


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Cost of goods sold and cost of revenue:
Product revenue	$	18,023	$	13,983	$	56,651	$	44,006
Services		—		271		347		698
Total cost of goods sold and cost of revenue	$	18,023	$	14,254	$	56,998	$	44,704

Insider Trading Arrangements

3 Months Ended

Sep. 30, 2024

Trading Arrangements, by Individual

Material Terms of Trading Arrangement

During the three months ended September 30, 2024, two of our officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted written trading plans for the orderly disposition of the Company’s securities as set forth in the table below:

       
      Type of Trading Arrangement

      Name and Position

      Action

      Adoption
Date

      Rule 
10b5-1(1)

      Non-Rule 
10b5-1(2)

      Total Shares of Common Stock to be Sold (3)

      Expiration Date

Steven B. Binder
Director

Adoption

August 16, 2024

X

—

297,075

August 29, 2025

David Thomson
EVP, General Counsel

Adoption

August 19, 2024

X

—

188,780

August 19, 2025

_________________________

(1) Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.

(2) "Non-Rule 10b5-1 trading arrangement" as defined in Item 408(c) of Regulation S-K under the Exchange Act.

(3) These trading plans include the potential exercise and sale by Steven Binder and David Thomson of short-dated options exercisable for up to 135,075 and 147,780 shares of common stock, respectively. The remainder of each plan is designed to sell a specified percentage of the net shares delivered after tax withholding upon the vesting of restricted stock unit awards held by each individual. The actual number of shares to be sold will depend on state and federal tax rates applicable on the relevant vesting dates (currently assumed to be a combined 34%) as well as the payout, if any, of market RSU awards that will deliver a number of shares determined by the percentile ranking of MannKind total shareholder return ("TSR") over a three-year measurement period relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period (currently assumed to be 100% of target). Based on these assumptions, the number of shares of common stock to be sold by Steven Binder and David Thomson after tax withholdings approximate 162,000 and 41,000, respectively, for total estimated shares of common stock to be sold of up to 297,075 and 188,780, respectively.

Steven B. Binder

Trading Arrangements, by Individual

Name

Steven B. Binder

Title

Director

Rule 10b5-1 Arrangement Adopted

true

Non-Rule 10b5-1 Arrangement Adopted

false

August 16, 2024

August 29, 2025

379 days

297,075

Trading Arrangements, by Individual

Name

David Thomson

Title

EVP, General Counsel

Rule 10b5-1 Arrangement Adopted

true

Non-Rule 10b5-1 Arrangement Adopted

false

August 19, 2024

August 19, 2025

366 days

188,780

Stock-Based Compensation Expense - Schedule of Employee Awards and Non-employee Director Award Plan Activity (Details) - shares	3 Months Ended			9 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2024
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Granted awards	241,253	5,630,286	267,990	6,139,529
Employees Awards \| RSUs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Granted awards	241,253	3,205,910	267,990	3,715,153
Employees Awards \| Market RSUs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Granted awards		2,144,000		2,144,000
Non-employee Directors Awards \| RSUs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Granted awards		280,376		280,376

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 1D
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Pulmatrix Transaction - Additional Information (Detail)			1 Months Ended		3 Months Ended
Pulmatrix Transaction - Additional Information (Detail)	Jul. 08, 2024 USD ($) Employees	May 28, 2024	Jul. 31, 2024 USD ($)	Jun. 30, 2024 USD ($)	Sep. 30, 2024 USD ($)	Dec. 31, 2023
Business Acquisition [Line Items]
Number of pulmatrix employees which began employment \| Employees	13
Incremental borrowing rate	7.25%				7.25%	7.25%
Letters of credit secured by cash held in restricted depository account				$ 700,000
Lease term extension period				Effective Date through November 30, 2033
Lease monthly payments				$ 100,000
Percentage of annual increment on lease				3.00%
Transaction costs					$ 100,000
Pulmatrix, Inc
Business Acquisition [Line Items]
Asset acquisition, date of acquisition agreement		May 28, 2024
Asset acquisition, effective date of acquisition	Jul. 08, 2024
Fair value of iSPERSE license	$ 4,300,000
Lease monthly payments			$ 101,282
Percentage of annual increment on lease			3.00%

Borrowings - Summary of Carrying Amount of Borrowings (Detail) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Debt Instrument [Line Items]
Senior convertible notes	$ 227,941	$ 226,851
Mann Group convertible note	227,941	226,851
Total debt — net carrying amount	$ 227,941	268,699
MidCap Credit Facility
Debt Instrument [Line Items]
Credit Facility		33,019
Related Party
Debt Instrument [Line Items]
Mann Group convertible note		$ 8,829

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 55
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482949/835-30-55-8

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(f))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69F
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1D
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1D
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1D
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482900/835-30-50-1

+ Details

- Definition

The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.

+ References + Details

- Definition

Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.

+ References + Details

Borrowings (Tables)

9 Months Ended

Sep. 30, 2024

Debt Disclosure [Abstract]

Summary of Carrying Amount of Borrowings

Carrying amount of the Company's borrowings consisted of the following (in thousands):


	September 30, 2024		December 31, 2023
Senior convertible notes	$	227,941	$	226,851
MidCap credit facility		—		33,019
Mann Group convertible note		—		8,829
Total debt – net carrying amount	$	227,941	$	268,699

Schedule of Line of Credit Facility Debt and Key Terms

The following table provides a summary of the Company’s principal balance of debt and key terms:

         
        Amount Due

        Terms

         
        September 30, 2024

        December 31, 2023

        Annual Interest
   Rate

        Maturity Date

        Conversion Price

        Senior convertible notes

        $230.0 million

        $230.0 million

        2.50%

        March 2026

        $5.21 
per share

MidCap credit facility(1)

—

$33.3 million

one-month
SOFR
(1% floor)
plus 6.25%;
cap of 8.25%

August 2025

N/A

Mann Group convertible note(2)

—

$8.8 million

2.50%

December 2025

$2.50
per share

_________________________

(1)

Repaid on April 1, 2024.

(2)

Repaid on April 2, 2024.

Schedule of Maturities of Company's Borrowings

The maturities of the Company’s borrowings as of September 30, 2024 are as follows (in thousands):


	Amounts
Remainder of 2024	$	—
2025		—
2026		230,000
Total principal payments		230,000
Debt issuance costs		(2,059	)
Total debt	$	227,941

Schedule of Amortization of Premium and Accretion of Debt Issuance Costs

Amortization of the premium and accretion of debt issuance costs related to all borrowings were as follows (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Amortization of debt discount and prepayment fee	$	—	$	109	$	85	$	323
Amortization of debt issuance cost		363		363		1,175		1,090

Description of Business and Significant Accounting Policies - Additional Information (Detail 1) - Collaborations and services	Sep. 30, 2024
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2023-04-01
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Remaining performance obligation, Expected timing of satisfaction, period	12 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2024-04-01
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Remaining performance obligation, Expected timing of satisfaction, period	12 months

Pulmatrix Transaction (Tables)

9 Months Ended

Sep. 30, 2024

Business Acquisition [Line Items]

Schedule of Fair Value of Identifiable Assets Acquired and Liabilities Assumed

The fair values of identifiable assets acquired and liabilities assumed by the Company from Pulmatrix as of the Effective Date are reflected below (in thousands):


	Amount
Assets:
iSPERSE License – IPR&D	$	4,300
Right-of-use asset – Bedford R&D facility		10,057
Property and equipment		959
Total assets		15,316
Liabilities:
Operating lease liability – Bedford R&D facility		10,057
Total liabilities		10,057
Net assets acquired – Gain on bargain purchase	$	5,259

Investments

9 Months Ended

Sep. 30, 2024

Schedule Of Investments [Abstract]

Investments

3. Investments

Cash Equivalents — Cash equivalents consist of highly liquid investments with original or remaining maturities of 90 days or less at the time of purchase that are readily convertible into cash.

Available-for-Sale Investment — The Company's investment in Thirona is comprised of two notes with aggregate face value of $8.0 million and stated interest rate of 10%. The Thirona convertible notes are classified as available-for-sale securities and are included in other assets as of September 30, 2024 and prepaid expenses and other current assets as of December 31, 2023 in the condensed consolidated balance sheets. Available-for-sale investments are measured at fair value with realized gains and losses reported in other income (expense) in the condensed consolidated statements of operations. Unrealized holding gains and losses are excluded from earnings and reported in other comprehensive income (loss) until realized. The Company determines the fair value of its available-for-sale investments using level 3 inputs and evaluates the fair value of its investment in Thirona by applying a scenario based method with a hypothetical yield of 28.0% and 35.0%, and volatility of 70.0% and 90.0% at September 30, 2024 and December 31, 2023, respectively. As of September 30, 2024 and December 31, 2023, the fair value of the Company's investment in Thirona was $5.9 million and $6.9 million, respectively. For the three and nine months ended September 30, 2024, the Company recorded an unrealized holding gain of $0.6 million. Additionally, for the nine months ended September 30, 2024, the Company recognized a loss of $1.6 million on its investment in Thirona as a result of modification of the Thirona convertible notes. For the three and nine months ended September 30, 2023, the Company recognized a gain of $0.9 million on its investment in Thirona as a result of the recovery of a temporary impairment and an unrealized holding gain of $0.4 million. For the three and nine months ended September 30, 2024, the Company recognized no interest income on investment and $0.1 million and $0.4 million for the three and nine months ended September 30, 2023, respectively.

Held-to-Maturity Investments — Investments consist of highly liquid investments that are intended to facilitate liquidity and capital preservation. The amortization or accretion of the Company’s investments is recognized in the condensed consolidated statements of operations as interest income. For the three and nine months ended September 30, 2024, the Company recognized $3.2 million and $9.8 million, respectively, of interest income on investments, of which $2.1 million and $6.0 million, respectively, was net accretion on certain investments. For the three and nine months ended September 30, 2023, the Company recognized $1.5 million and $4.0 million, respectively, of interest income on investments, of which $0.5 million and $0.9 million, respectively, was net accretion on certain investments. No allowance for credit losses on held-to-maturity securities was required as of September 30, 2024 or December 31, 2023.

The contractual maturities of the Company’s held-to-maturity investments are summarized below (in thousands):


	September 30, 2024				December 31, 2023
	Amortized Cost Basis		Aggregate Fair Value		Amortized Cost Basis		Aggregate Fair Value
Due in one year or less(1)	$	230,797	$	231,555	$	115,263	$	115,374
Due after one year through five years		16,796		16,992		7,155		7,197
Total	$	247,593	$	248,547	$	122,418	$	122,571

___________________________

(1)

The investments due in one year or less include cash equivalents of $41.6 million as of September 30, 2024 and $58.6 million as of December 31, 2023.

The fair value of the cash equivalents, long-term and short-term investments are disclosed below (dollars in thousands).


	September 30, 2024
	Investment Level	Amortized Cost (Carrying Value)			Gross Unrealized Holding Gains		Gross Unrealized Holding Losses			Estimated Fair Value
Money market funds and other	Level 1	$	31,298		$	—	$	—		$	31,298
Commercial bonds and paper	Level 2		57,477			268		(12	)		57,733
U.S. Treasury Securities	Level 2		158,818			700		(2	)		159,516
Total cash equivalents and investments			247,593			968		(14	)		248,547
Less: cash equivalents			(41,582	)		—		—			(41,582	)
Total Investments		$	206,011		$	968	$	(14	)	$	206,965


	December 31, 2023
	Investment Level	Amortized Cost (Carrying Value)			Gross Unrealized Holding Gains		Gross Unrealized Holding Losses			Estimated Fair Value
Money market funds	Level 1	$	69,611		$	—	$	—		$	69,611
Commercial bonds and paper	Level 2		43,251			135		(38	)		43,348
U.S. Treasury Securities	Level 2		9,556			56		—			9,612
Total cash equivalents and investments			122,418			191		(38	)		122,571
Less: cash equivalents			(58,644	)		—		—			(58,644	)
Total Investments		$	63,774		$	191	$	(38	)	$	63,927

As of September 30, 2024 and December 31, 2023, there was $1.1 million and $0.5 million, respectively, of accrued interest receivable on investments which is included in prepaid expense and other current assets in our condensed consolidated balance sheets.

Inventories (Tables)

9 Months Ended

Sep. 30, 2024

Inventory Disclosure [Abstract]

Components of Inventory

Inventories consist of the following (in thousands):


	September 30, 2024		December 31, 2023
Raw materials	$	6,437	$	6,262
Work-in-process		9,074		13,646
Finished goods		11,152		8,637
Total inventory	$	26,663	$	28,545

Investments - Schedule of Contractual Maturities of Held to Maturity Investments (Parenthetical) (Detail) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Schedule of Held-to-Maturity Securities [Line Items]
Cash and cash equivalents	$ 62,373	$ 238,480
Due in One Year or Less
Schedule of Held-to-Maturity Securities [Line Items]
Cash and cash equivalents	$ 41,600	$ 58,600

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (aaa)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (f)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (f)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (f)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (f)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5A

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5A
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5A

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5A
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5A

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5B

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5B

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5B
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5B

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5B
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5B

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5B

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5

+ Details

Goodwill and Other Intangible Assets - Summary of Other Intangible Asset (Detail) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Finite Lived Intangible Assets [Line Items]
Cost	$ 5,500	$ 1,200
Accumulated Amortization	(187)	(127)
Net Book Value	5,313	1,073
iSPERSE License - IPR&D
Finite Lived Intangible Assets [Line Items]
Cost	4,300
Net Book Value	$ 4,300
Developed Technology
Finite Lived Intangible Assets [Line Items]
Estimated Useful Life (Years)	15 years
Cost	$ 1,200	1,200
Accumulated Amortization	(187)	(127)
Net Book Value	$ 1,013	$ 1,073

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References + Details

Earnings Per Common Share

9 Months Ended

Sep. 30, 2024

Earnings Per Share [Abstract]

Earnings Per Common Share

13. Earnings per Common Share

The following tables summarize the components of the basic and diluted EPS computations (in thousands, except per share amounts):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
EPS — basic:
Net income (loss) (numerator)	$	11,550	$	1,721	$	20,166	$	(13,339	)
Weighted average common shares (denominator)		274,998		268,732		272,811		266,126
Net income (loss) per share	$	0.04	$	0.01	$	0.07	$	(0.05	)
EPS — diluted:
Adjusted net income (loss) (numerator)	$	11,550	$	3,578	$	20,166	$	(13,339	)
Weighted average common shares		274,998		268,732		272,811		266,126
Effect of dilutive securities — common shares issuable		9,695		55,038		8,596		—
Adjusted weighted average common shares (denominator)		284,693		323,770		281,407		266,126
Net income (loss) per share	$	0.04	$	0.01	$	0.07	$	(0.05	)

For the three months ended September 30, 2024, diluted net income per share excluded the weighted average effect of 10.4 million shares of RSUs and Market RSUs, 0.4 million options and PNQs and 44.1 million common shares issuable upon conversion of our Senior convertible notes, as they were antidilutive. For the nine months ended September 30, 2024, diluted net income per share

excluded the weighted average effect of 9.1 million RSUs and Market RSUs, 0.7 million options and PNQs and 44.1 million common shares issuable upon conversion of our Senior convertible notes, as they were antidilutive.

For the three months ended September 30, 2023, diluted net income per share excluded the weighted average effect of 9.4 million shares of RSUs and Market RSUs and 2.0 million options and PNQs as they were antidilutive.

Common shares issuable represents incremental shares of common stock which consist of RSUs, stock options, warrants, and shares that could be issued upon conversion of the Senior convertible notes and the Mann Group convertible notes. Potentially dilutive securities outstanding which were considered antidilutive due to the net losses incurred for the nine months ended September 30, 2023 are summarized as follows (in shares):


	September 30,
	2023
Senior convertible notes		44,120,463
RSUs and Market RSUs(1)		21,151,454
Common stock options and PNQs		8,447,339
Mann Group convertible notes		3,370,000
Total shares		77,089,256

__________________________

(1)

Market RSUs issued in 2021, 2022 and 2023 are included at the share delivery of 0%, 205% and 219%, respectively, in accordance with a valuation assessment obtained as of September 30, 2023.

Condensed Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Statement Of Income And Comprehensive Income [Abstract]
Net income (loss)	$ 11,550	$ 1,721	$ 20,166	$ (13,339)
Other comprehensive income:
Unrealized gain on available-for-sale securities	588		588	443
Comprehensive income (loss)	$ 12,138	$ 1,721	$ 20,754	$ (12,896)

- Definition

Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

+ Details

- Definition

Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.

+ References + Details

Accounts Receivable - Additional Information (Detail)	3 Months Ended	9 Months Ended	12 Months Ended
Accounts Receivable - Additional Information (Detail)	Sep. 30, 2024 USD ($)	Sep. 30, 2024 USD ($) Distributor	Dec. 31, 2023 USD ($) Distributor
Accounts Receivable [Line Items]
Number of wholesale distributors \| Distributor		3	3
Percentage of gross sales from major wholesale distributors	77.00%	73.00%
Allowance for credit losses and doubtful accounts	$ 0	$ 0	$ 0
Percentage of revenue from major customers collaborations and services	100.00%	100.00%
Zealand Pharma US
Accounts Receivable [Line Items]
Allowance for credit losses and doubtful accounts			$ 200,000
United Therapeutics Corporation
Accounts Receivable [Line Items]
Percentage of collaborations and services net accounts receivables		100.00%	100.00%
Commercial product sales
Accounts Receivable [Line Items]
Percentage of accounts receivable from major wholesale distributors	87.00%	87.00%
Allowance for credit losses and doubtful accounts	$ 0	$ 0	$ 157,000
Accounts receivable	$ 18,359,000	$ 18,359,000	$ 20,199,000

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 62,373	$ 238,480
Short-term investments	189,215	56,619
Accounts receivable, net	18,184	14,901
Inventory	26,663	28,545
Prepaid expenses and other current assets	31,229	34,848
Total current assets	327,664	373,393
Restricted cash	735
Long-term investments	16,796	7,155
Property and equipment, net	85,339	84,220
Goodwill	1,931	1,931
Other intangible assets	5,313	1,073
Other assets	26,422	7,426
Total assets	464,200	475,198
Current liabilities:
Accounts payable	6,444	9,580
Accrued expenses and other current liabilities	37,386	42,036
Liability for sale of future royalties - current	11,755	9,756
Financing liability - current	9,998	9,809
Deferred revenue — current	6,518	9,085
Recognized loss on purchase commitments — current		3,859
Midcap credit facility - current		20,000
Total current liabilities	72,101	104,125
Senior convertible notes	227,941	226,851
Liability for sale of future royalties - long term	137,140	136,054
Financing liability - long term	94,005	94,319
Deferred revenue — long term	65,150	69,794
Recognized loss on purchase commitments — long term	62,638	60,942
Operating lease liability	12,167	3,925
Milestone liabilities	2,813	3,452
Financing lease liability	171
Mann Group convertible note		8,829
Accrued interest - Mann Group convertible note		56
Midcap credit facility - long term		13,019
Total liabilities	674,126	721,366
Commitments and contingencies (Note 15)
Stockholders' deficit:
Undesignated preferred stock, $0.01 par value -- 10,000,000 shares authorized; no shares issued or outstanding as of September 30, 2024 or December 31, 2023
Common stock, $0.01 par value -- 800,000,000 shares authorized; 275,775,038 and 270,034,495 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively	2,753	2,700
Additional paid-in capital	2,995,974	2,980,539
Accumulated other comprehensive income	588
Accumulated deficit	(3,209,241)	(3,229,407)
Total stockholders' deficit	(209,926)	(246,168)
Total liabilities and stockholders' deficit	$ 464,200	$ 475,198

Investments - Schedule of Contractual Maturities of Held to Maturity Investments (Detail) - USD ($)
$ in Thousands

Sep. 30, 2024

Dec. 31, 2023

Debt Securities, Held-to-Maturity, Maturity [Abstract]

Amortized cost basis, due in one year or less

^[1]

$ 230,797

$ 115,263

Amortized cost basis due after one year through five years

16,796

7,155

Amortized cost basis, total

247,593

122,418

Aggregate fair value, due in one year or less

^[1]

231,555

115,374

Aggregate fair value, due after one year through five years

16,992

7,197

Aggregate fair value, total

$ 248,547

$ 122,571

[1]	The investments due in one year or less include cash equivalents of $41.6 million as of September 30, 2024 and $58.6 million as of December 31, 2023.

Property and Equipment (Tables)

9 Months Ended

Sep. 30, 2024

Property Plant And Equipment [Abstract]

Property and Equipment, Net

Property and equipment consisted of the following (dollars in thousands):


	Estimated Useful
	Life (Years)		September 30, 2024			December 31, 2023
Land		—	$	875		$	875
Buildings	39-40			17,389			17,389
Building improvements(1)	5-40			90,573			46,357
Machinery and equipment	3-15			65,733			60,410
Furniture, fixtures and office equipment	5-10			3,350			3,070
Computer equipment and software		3		8,811			8,658
Construction in progress(1)		—		5,242			48,997
Total property and equipment				191,973			185,756
Less accumulated depreciation				(106,634	)		(101,536	)
Total property and equipment, net			$	85,339		$	84,220

___________________________

(1)

Depreciation Expense Related to Property and Equipment

Depreciation expense related to property and equipment was as follows (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Depreciation Expense	$	2,099	$	1,117	$	5,151	$	3,250

Borrowings - Schedule of Maturities of Company's Borrowings (Detail) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Debt Disclosure [Abstract]
Remainder of 2024	$ 0
2025	0
2026	230,000
Total principal payments	230,000
Debt issuance costs	(2,059)
Total debt — net carrying amount	$ 227,941	$ 268,699

- Definition

Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.

+ References + Details

Fair Value of Financial Instruments (Tables)

9 Months Ended

Sep. 30, 2024

Fair Value Disclosures [Abstract]

Fair Value of Financial Instruments

The following tables set forth the fair value of the Company’s financial instruments (Level 3 in the fair value hierarchy) (in millions):


	September 30, 2024
			Fair Value
	Carrying Value		Significant Unobservable Inputs (Level 3)
Financial liabilities:
Senior convertible notes(1)	$	227.9	$	284.7
Milestone rights(2)		3.2		11.3
Contingent milestone liability(3)		0.3		0.3
Financing liability(4)		104.0		106.5
Liability for sale of future royalties(5)		147.5		137.4

_________________________

(1)

Fair value was determined by applying a discounted cash flow analysis to the straight note with a hypothetical yield of 11.0%, volatility of 52.0% and a Monte Carlo simulation for the value of the conversion feature. A change in yield of + or – 2% would result in a fair value of $279.6 million and $290.0 million, respectively.

(2)

Fair value was determined by applying a Monte Carlo simulation method for the calculation of the potential payment and the Geometric Brownian Motion forecasting model to estimate the underlying revenue. Market based inputs and other level 3 inputs were used to forecast future revenue. The key inputs used included a risk-free rate of 3.7%, dividend yield of 0.0%, volatility of 50.0%, period of 7.3 years and credit risk of 15.0%.

(3)

Fair value was determined by using the Monte Carlo simulation method for the calculation of the potential payment and the Geometric Brownian Motion forecasting model to estimate the underlying revenue. Market based inputs and other level 3 inputs were used to forecast future revenue. The key inputs used included a risk-free rate of 3.9%, dividend yield of 0.0%, volatility of 43.0%, period of 13.3 years and credit risk of 15.0%.

(4)

Fair value was determined by applying a discounted cash flow analysis with a hypothetical yield of 9.5%. A change in yield of + or – 2% would result in a fair value of $94.1 million and $121.8 million, respectively.

(5)

At September 30, 2024, fair value was determined by applying a discounted cash flow analysis with a hypothetical yield of 11.0%. A change in yield of + or – 2% would result in a fair value of $121.9 million and $156.4 million, respectively. At December 31, 2023, the carrying value approximated the fair value.


	December 31, 2023
			Fair Value
	Carrying Value		Significant Unobservable Inputs (Level 3)
Financial liabilities:
Senior convertible notes(1)	$	226.9	$	231.3
MidCap credit facility(2)		33.0		35.5
Mann Group convertible note(3)		8.8		14.4
Milestone rights(4)		3.9		11.9
Contingent milestone liability(5)		0.3		0.3
Financing liability(6)		104.1		106.8

_________________________

(1)

Fair value was determined by applying a discounted cash flow analysis to the straight note with a hypothetical yield of 11.0%, volatility of 62.7% and a Monte Carlo simulation for the value of the conversion feature. A change in yield of + or – 2% would result in a fair value of $224.1 million and $238.9 million, respectively.

(2)

Fair value was determined by applying a discounted cash flow analysis with a hypothetical yield of 12.0%. A change in yield of + or – 2% would result in a fair value of $35.0 million and $36.0 million, respectively.

(3)

Fair value was determined by applying a discounted cash flow analysis with a hypothetical yield of 13.0% and volatility of 62.7% to the straight note and a binomial option pricing model for the value of the conversion feature. A change in yield of + or – 2% would result in a fair value of $14.2 million and $14.7 million, respectively.

(4)

Fair value was determined by applying a Monte Carlo simulation method for the calculation of the potential payment and the Geometric Brownian Motion forecasting model to estimate the underlying revenue. Market based inputs and other level 3 inputs were used to forecast future revenue. The key inputs used included a risk-free rate of 3.9%, dividend yield of 0.0%, volatility of 50.0%, period of 8 years and credit risk of 17.0%.

(5)

Fair value was determined by using the Monte Carlo simulation method for the calculation of the potential payment and the Geometric Brownian Motion forecasting model to estimate the underlying revenue. Market-based inputs and other level 3 inputs were used to forecast future revenue. The key inputs used included a risk-free rate of 4.0%, dividend yield of 0.0%, volatility of 43.0%, period of 15 years and credit risk of 17.0%.

(6)

Fair value was determined by applying a discounted cash flow analysis with a hypothetical yield of 9.5%.

Commitments and Contingencies - Remaining Purchase Commitments and Estimated Capacity Fee Liability Requirements (Parenthetical) (Details)	Sep. 30, 2024 EUR (€)
Purchase Obligation Fiscal Year Maturity [Abstract]
Capacity fee	€ 750,000

Collaboration, Licensing and Other Arrangements - Additional Information (Detail) - USD ($)

1 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

Oct. 31, 2018

Dec. 31, 2023

Dec. 31, 2022

May 31, 2018

Sep. 30, 2024

Mar. 31, 2024

Sep. 30, 2023

Sep. 30, 2024

Sep. 30, 2023

Dec. 31, 2023

Feb. 28, 2023

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Deferred revenue - current

$ 9,085,000

$ 6,518,000

$ 9,085,000

Deferred revenue - non-current

69,794,000

65,150,000

69,794,000

Total revenue from UT

70,079,000

$ 51,253,000

208,728,000

$ 140,490,000

Collaborations and services

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Total revenue from UT

23,268,000

13,108,000

74,130,000

35,705,000

AFREZZA product sales

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Total revenue from UT

19,728,000

17,927,000

59,272,000

53,834,000

United Therapeutics Corporation

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Total revenue from UT

50,314,000

33,289,000

149,346,000

86,546,000

United Therapeutics Corporation | Manufacturing Services

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Funding for development of alternative manufacturing processes

$ 2,300,000

United Therapeutics Corporation | Commercialization and Continuous Improvement Activities

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Funding for capital improvements

39,500,000

Thirona Bio, Inc.

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Minimum amount to expended

$ 1,100,000

Funded amount

1,100,000

Collaboration and License Agreement | United Therapeutics Corporation

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Total anticipated cash flows

^[1]

722,300,000

Deferred revenue

77,500,000

70,500,000

77,500,000

Deferred revenue - current

8,900,000

6,400,000

8,900,000

Deferred revenue - non-current

$ 68,600,000

64,100,000

$ 64,100,000

68,600,000

Royalty percentage

10.00%

Royalty future net sales percentage

1.00%

Royalty retaining percentage

9.00%

License agreement description

Collaboration and License Agreement | United Therapeutics Corporation | Manufacturing Services

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Total anticipated cash flows

722,300,000

Collaboration and License Agreement | United Therapeutics Corporation | Next-Gen R&D Services | Transaction Price For The Performance Obligations

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Total anticipated cash flows

$ 602,300,000

Commercial Supply Agreement | United Therapeutics Corporation | Collaborations and services

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Total revenue from UT

23,231,000

12,800,000

$ 73,673,000

34,897,000

Supply and Distribution Agreement | AFREZZA product sales | Biomm

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Total revenue from UT

$ 0

License and Distribution Agreement | Cipla Ltd

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Deferred revenue

$ 1,400,000

1,200,000

1,400,000

Deferred revenue - current

200,000

100,000

200,000

Deferred revenue - non-current

$ 1,200,000

1,100,000

$ 1,200,000

Marketing and distribution agreement date

2018-05

License and Distribution Agreement | Collaborations and services | Cipla Ltd

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Total revenue from UT

$ 37,000

$ 110,000

[1]

The total anticipated cash flow includes a transaction price of $120.0 million for the contractual obligations under the CSA for the Manufacturing Services and Product Sales and the Next-Gen R&D Services performance obligations and $602.3 million for future supply of Tyvaso DPI over the remaining term of the CSA.

Fair Value of Financial Instruments - Fair Value of Financial Instruments (Detail) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Carrying Amount \| MidCap Credit Facility
Financial liabilities:
Total financial liabilities fair value		$ 33.0
Carrying Amount \| Senior Convertible Notes
Financial liabilities:
Total financial liabilities fair value	$ 227.9	226.9
Carrying Amount \| Mann Group Convertible Note
Financial liabilities:
Total financial liabilities fair value		8.8
Carrying Amount \| Milestone Rights
Financial liabilities:
Total financial liabilities fair value	3.2	3.9
Carrying Amount \| Contingent Milestone Liability
Financial liabilities:
Total financial liabilities fair value	0.3	0.3
Carrying Amount \| Financing Liability
Financial liabilities:
Total financial liabilities fair value	104.0	104.1
Carrying Amount \| Liability for Sale of Future Royalties
Financial liabilities:
Total financial liabilities fair value	147.5
Estimate of Fair Value Measurement \| Fair Value, Inputs, Level 3 \| MidCap Credit Facility
Financial liabilities:
Total financial liabilities fair value		35.5
Estimate of Fair Value Measurement \| Senior Convertible Notes \| Fair Value, Inputs, Level 3
Financial liabilities:
Total financial liabilities fair value	284.7	231.3
Estimate of Fair Value Measurement \| Mann Group Convertible Note \| Fair Value, Inputs, Level 3
Financial liabilities:
Total financial liabilities fair value		14.4
Estimate of Fair Value Measurement \| Milestone Rights \| Fair Value, Inputs, Level 3
Financial liabilities:
Total financial liabilities fair value	11.3	11.9
Estimate of Fair Value Measurement \| Contingent Milestone Liability \| Fair Value, Inputs, Level 3
Financial liabilities:
Total financial liabilities fair value	0.3	0.3
Estimate of Fair Value Measurement \| Financing Liability \| Fair Value, Inputs, Level 3
Financial liabilities:
Total financial liabilities fair value	106.5	$ 106.8
Estimate of Fair Value Measurement \| Liability for Sale of Future Royalties \| Fair Value, Inputs, Level 3
Financial liabilities:
Total financial liabilities fair value	$ 137.4

Schedule of Accounts Receivable, Net (Detail) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Accounts Receivable [Line Items]
Allowance for credit losses	$ 0	$ 0
Total accounts receivable, net	18,184,000	14,901,000
Commercial product sales
Accounts Receivable [Line Items]
Accounts receivable, gross	18,359,000	20,199,000
Wholesaler distribution fees and prompt pay discounts	(2,363,000)	(2,469,000)
Reserve for returns	(7,817,000)	(6,215,000)
Allowance for credit losses	0	(157,000)
Total accounts receivable, net	8,179,000	11,358,000
Collaborations and services
Accounts Receivable [Line Items]
Total accounts receivable, net	$ 10,005,000	$ 3,543,000

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2024	Oct. 25, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2024
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q3
Trading Symbol	MNKD
Entity Registrant Name	MannKind Corporation
Entity Central Index Key	0000899460
Entity Current Reporting Status	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Shell Company	false
Entity Small Business	false
Entity Emerging Growth Company	false
Entity File Number	000-50865
Entity Tax Identification Number	13-3607736
Entity Address, Address Line One	1 Casper Street
Entity Address, City or Town	Danbury
Entity Address, State or Province	CT
Entity Address, Postal Zip Code	06810
City Area Code	818
Local Phone Number	661-5000
Entity Common Stock, Shares Outstanding		275,777,693
Document Quarterly Report	true
Document Transition Report	false
Entity Incorporation, State or Country Code	DE
Title of 12(b) Security	Common Stock, par value $0.01 per share
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes

Commitments and Contingencies - Schedule of Lease Term and Discount Rate (Detail) - USD ($) $ in Thousands	Sep. 30, 2024	Jul. 08, 2024	Dec. 31, 2023
Commitments And Contingencies Disclosure [Abstract]
Operating lease, right-of-use asset	$ 13,637		$ 4,685
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Other assets		Other assets
Operating lease liability-current	$ 2,431		$ 1,423
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Accrued expenses and other current liabilities		Accrued expenses and other current liabilities
Operating lease liability	$ 12,167		$ 3,925
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Operating lease liability		Operating lease liability
Total	$ 14,598		$ 5,348
Weighted average remaining lease term (in years)	7 years 3 months 18 days		3 years 8 months 12 days
Incremental borrowing rate	7.25%	7.25%	7.25%

Fair Value of Financial Instruments

9 Months Ended

Sep. 30, 2024

Fair Value Disclosures [Abstract]

Fair Value of Financial Instruments

11. Fair Value of Financial Instruments

The availability of observable inputs can vary among the various types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level input that is significant to the overall fair value measurement. The Company uses the exit price method for estimating the fair value of loans for disclosure purposes. Inputs used in the valuation techniques to derive fair values are classified based on a three-level hierarchy, as follows:

Level 1 — Quoted prices for identical instruments in active markets.

Level 2 — Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.

Level 3 — Significant inputs to the valuation model are unobservable.

The carrying amounts reported in the condensed consolidated financial statements for cash, accounts receivable, accounts payable, and accrued expenses and other current liabilities (excluding the Milestone Rights liability) approximate their fair value due to their relatively short maturities. The fair value of the Senior convertible notes, MidCap credit facility, Mann Group convertible note, Milestone Rights liability, Contingent milestone liability, Financing liability and Liability for sale of future royalties are disclosed below.

Financial Liabilities — The following tables set forth the fair value of the Company’s financial instruments (Level 3 in the fair value hierarchy) (in millions):


	September 30, 2024
			Fair Value
	Carrying Value		Significant Unobservable Inputs (Level 3)
Financial liabilities:
Senior convertible notes(1)	$	227.9	$	284.7
Milestone rights(2)		3.2		11.3
Contingent milestone liability(3)		0.3		0.3
Financing liability(4)		104.0		106.5
Liability for sale of future royalties(5)		147.5		137.4

_________________________

(1)

(2)

(3)

(4)

(5)


	December 31, 2023
			Fair Value
	Carrying Value		Significant Unobservable Inputs (Level 3)
Financial liabilities:
Senior convertible notes(1)	$	226.9	$	231.3
MidCap credit facility(2)		33.0		35.5
Mann Group convertible note(3)		8.8		14.4
Milestone rights(4)		3.9		11.9
Contingent milestone liability(5)		0.3		0.3
Financing liability(6)		104.1		106.8

_________________________

(1)

(2)

(3)

(4)

Fair value was determined by applying a Monte Carlo simulation method for the calculation of the potential payment and the Geometric Brownian Motion forecasting model to estimate the underlying revenue. Market based inputs and other level 3 inputs were used to forecast future revenue. The key inputs used included a risk-free rate of 3.9%, dividend yield of 0.0%, volatility of 50.0%, period of 8 years and credit risk of 17.0%.

(5)

Fair value was determined by using the Monte Carlo simulation method for the calculation of the potential payment and the Geometric Brownian Motion forecasting model to estimate the underlying revenue. Market-based inputs and other level 3 inputs were used to forecast future revenue. The key inputs used included a risk-free rate of 4.0%, dividend yield of 0.0%, volatility of 43.0%, period of 15 years and credit risk of 17.0%.

(6)

Fair value was determined by applying a discounted cash flow analysis with a hypothetical yield of 9.5%.

Milestone Rights Liability — The fair value measurement of the Milestone Rights liability is sensitive to the discount rate and the timing of achievement of milestones. The Company utilized a Monte-Carlo Simulation Method to simulate the Afrezza net sales under

a neutral framework to estimate the potential payments and the Geometric Brownian Motion forecasting model to estimate the underlying revenue. The Company then discounted the future expected payments at cost of debt with a term equal to the simulated time to payout based on cumulative sales. See Note 15 – Commitments and Contingencies.

Contingent Milestone Liability — The acquisition of V-Go in May 2022 resulted in a contingent milestone liability which could result in obligations to the seller if certain revenue thresholds are met. The initial fair value of the contingent milestone liability was recorded as an adjustment to the purchase price. Subsequent changes in the fair value are reported in general and administrative expenses.

Financing Liability — The Sale-Leaseback Transaction in November 2021 resulted in a financing liability. See Note 15 – Commitments and Contingencies.

Liability for Sale of Future Royalties — The sale of a portion of our royalty rights in December 2023 resulted in a liability for sale of future royalties. See Note 15 – Commitments and Contingencies.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 107
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-107

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 100
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-100

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 940
-SubTopic 820
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478119/940-820-50-1

+ Details

Collaboration, Licensing and Other Arrangements - Schedule of Revised Anticipated Cash Flows from Transactions Allocated Performance Obligations (Detail) - Collaboration and License Agreement - United Therapeutics Corporation
$ in Millions

1 Months Ended

Dec. 31, 2022

USD ($)

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Total anticipated cash flows

$ 722.3

^[1]

R&D Services and License | Over Time

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Progress Measure

Ratably

Recognition Period

Aug 2021 - Oct 2021

Next-Gen R&D Services | Over Time

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Anticipated Revenue Allocation

$ 10.0

Progress Measure

Input

Recognition Period

% of completion of costs

Manufacturing Services and Product Sales | Point In Time

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Anticipated Revenue Allocation

$ 712.3

^[2]

Recognition Period

Transfer of control

^[2]

[1]

[2]

The Manufacturing Services and Product Sales performance obligation will be recognized as control of manufactured products is transferred to UT. The modification did not result in a cumulative catch-up adjustment as a result of the revenue being deferred for the performance obligations that were affected by the modification. The allocation of the transaction price for the Manufacturing Services and Product Sales includes a material right related to the Company’s estimated production of product in the amount of $220.8 million. The Company will sell product to UT under individual purchase orders, which represent distinct performance obligations. The ultimate cash flows may vary as manufacturing purchase orders are received.

Goodwill and Other Intangible Assets

9 Months Ended

Sep. 30, 2024

Goodwill And Intangible Assets Disclosure [Abstract]

Goodwill and Other Intangible Assets

7. Goodwill and Other Intangible Assets

Goodwill — Goodwill represents the excess of the purchase price over the identifiable tangible and intangible assets acquired plus liabilities assumed arising from business combinations. The balance of goodwill was $1.9 million as of September 30, 2024 and December 31, 2023 as a result of the Company's acquisition of V-Go in May 2022. Goodwill is tested at least annually for impairment by assessing qualitative factors in determining whether it is more likely than not that the fair value of net assets is below their carrying amounts. See Note 1 – Description of Business and Significant Accounting Policies.

Other Intangible Assets — Other intangible assets consisted of the following (dollars in thousands):


	Estimated		September 30, 2024							December 31, 2023
	Useful Life (Years)		Cost		Accumulated Amortization			Net Book Value		Cost		Accumulated Amortization			Net Book Value
Developed technology		15	$	1,200	$	(187	)	$	1,013	$	1,200	$	(127	)	$	1,073
iSPERSE License – IPR&D		—		4,300		—			4,300		—		—			—
Total			$	5,500	$	(187	)	$	5,313	$	1,200	$	(127	)	$	1,073

Amortization expense related to the developed technology was de minimis for the three and nine months ended September 30, 2024 and 2023. The estimated annual amortization expense for the developed technology for the years ended December 31, 2024 through 2028 is approximately $0.1 million per year and $0.6 million, thereafter.

The iSPERSE License — IPR&D is an indefinite-lived intangible asset, and as such is not amortized but rather is tested for impairment when facts or circumstances indicate the carrying value of the asset may not be recoverable. Upon completion of the underlying R&D efforts, the intangible asset will be accounted for as a finite-lived intangible asset. If the R&D efforts are abandoned, the IPR&D asset balance will be written off to R&D expense.

The Company evaluates its other intangible assets for potential impairment annually and when events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. See Note 1 – Description of Business and Significant Accounting Policies.

Stock-Based Compensation Expense

9 Months Ended

Sep. 30, 2024

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock-Based Compensation Expense

14. Stock-Based Compensation Expense

The Company granted the following awards (in shares):


	Three Months Ended March 31,			Three Months Ended June 30,			Three Months Ended September 30,			Nine Months Ended September 30,
	2024			2024			2024			2024
Employee awards:
RSUs		267,990	(1)		3,205,910	(2)		241,253	(5)		3,715,153
Market RSUs		—			2,144,000	(3)		—			2,144,000
Non-employee director RSUs		—			280,376	(4)		—			280,376
Total awards issued		267,990			5,630,286			241,253			6,139,529

_________________________

(1)

RSUs had a weighted average grant date fair value of $3.28 per share, of which 211,895 RSUs had a vesting period of 33.3% annually over the second, third, and fourth anniversary of the vesting determination date, 53,720 RSUs had a cliff vesting period of three years, and 2,375 RSUs had a vesting period of 25% annually over four years.

(2)

RSUs had a weighted average grant date fair value of $4.45 per share, of which 3,033,680 RSUs had a vesting period of 25% annually over four years, 145,980 RSUs had a vesting period of 33.3% annually over the second, third, and fourth anniversary of the vesting determination date, and 26,250 RSUs had a cliff vesting period of two years.

(3)

Market RSUs had a grant date fair value of $10.30 per share and will vest on July 15, 2027. The number of shares delivered on the vesting date is determined by the percentile ranking of MannKind total shareholder return ("TSR") over the period from July 1, 2024 until June 30, 2027 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above.

(4)

RSUs had a weighted average grant date fair value of $4.45 per share and vested immediately upon the grant date; however, the underlying shares of common stock will not be delivered until there is a separation of service such as resignation, retirement or death.

(5)

RSUs had a weighted average grant date fair value of $5.34 per share, of which 219,285 RSUs had a vesting period of 33.3% annually over the second, third, and fourth anniversary of the vesting determination date, and 21,968 RSUs had a vesting period of 40% on the first anniversary and 60% on the second anniversary of the vesting determination date.

As of September 30, 2024, there was $26.2 million and $27.4 million of unrecognized stock-based compensation expense related to RSUs and Market RSUs, respectively, which is expected to be recognized over a weighted average period of approximately 2.84 and 1.98 years, respectively.

Total stock-based compensation expense recognized in the condensed consolidated statements of operations as cost of goods sold, cost of revenue – collaborations and services, R&D and selling, general and administrative expense was as follows (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
RSUs and options	$	5,047	$	4,442	$	14,994	$	13,324
Employee stock purchase plan		180		159		546		512
Total	$	5,227	$	4,601	$	15,540	$	13,836

Employee Stock Purchase Plan

The Company provides all employees, including executive officers, the ability to purchase common stock at a discount under the ESPP. The ESPP is designed to comply with Section 423 of the Internal Revenue Code and provides all employees with the opportunity to purchase up to $25,000 worth of common stock (based on the undiscounted fair market value at the commencement of the offering period) each year at a purchase price that is the lower of 85% of the fair market value of the common stock on either the date of purchase or the commencement of the offering period. An employee may not purchase more than 5,000 shares of common stock on any purchase date. The executives’ rights under the ESPP are the same as those of all other employees.

There were approximately 2.6 million shares of common stock available for issuance under the ESPP as of September 30, 2024.

Earnings Per Common Share - Potential Dilutive Securities Outstanding that are Considered Antidilutive (Detail) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earnings per share				77,089,256
Senior Convertible Notes
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earnings per share	44,100,000		44,100,000	44,120,463
RSUs and Market RSUs
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earnings per share	10,400,000	9,400,000	9,100,000	21,151,454
Common Stock Options and PNQs
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earnings per share	400,000	2,000,000	700,000	8,447,339
Mann Group Convertible Notes
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earnings per share				3,370,000

Depreciation Expense Related to Property and Equipment (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Property Plant And Equipment [Abstract]
Depreciation Expense	$ 2,099	$ 1,117	$ 5,151	$ 3,250

Borrowings - Mann Group Promissory Notes - Additional Information (Detail) $ / shares in Units, $ in Thousands		1 Months Ended	9 Months Ended
	Apr. 02, 2024 USD ($) $ / shares shares	Aug. 31, 2019 USD ($) $ / shares	Sep. 30, 2024 USD ($) $ / shares shares	Sep. 30, 2023 USD ($) shares	Dec. 31, 2023 USD ($)
Debt Instrument [Line Items]
Debt instrument payment term description			Principal on each term loan advance under Tranche 1 and Tranche 2 was payable in 24 equal monthly installments that began September 1, 2023.
Maturity date		Dec. 31, 2025
Loss on extinguishment of debt			$ (7,050)
The Mann Group L L C
Debt Instrument [Line Items]
Loss on extinguishment of debt	$ 3,700
Debt instrument remaining principal and interest after conversion	$ 5,100
Conversion price \| $ / shares	$ 2.5
Debt issuance amount	$ 8,900
Conversion of notes to common shares, shares \| shares	1,500,000
convertible note plus accrued interest	$ 8,900
Convertible shares of common stock \| shares	3,554,198
Market value of common stock \| shares	2,054,198
The Mann Group L L C \| Convertible Promissory Note
Debt Instrument [Line Items]
Principal amount					$ 8,800
Senior notes, effective interest rate			2.50%
Conversion price \| $ / shares			$ 2.5
Conversion of notes to common shares, shares \| shares			15,285	37,122
The Mann Group L L C \| Convertible Promissory Note \| Accrued Interest
Debt Instrument [Line Items]
Debt issuance amount			$ 100	$ 200
The Mann Group L L C \| New Loan Arrangement \| Convertible Promissory Note
Debt Instrument [Line Items]
No of convertible shares		400
Principal amount per share \| $ / shares		$ 1,000
Conversion price \| $ / shares		$ 2.50
The Mann Group L L C \| New Loan Arrangement \| Promissory Notes
Debt Instrument [Line Items]
Senior notes, effective interest rate		2.50%
Debt instrument payment term description		quarterly
The Mann Group L L C \| Privately Negotiated Exchange Agreement \| Loan Arrangement
Debt Instrument [Line Items]
Common stock price per share \| $ / shares		$ 2.50
The Mann Group L L C \| Privately Negotiated Exchange Agreement \| Loan Arrangement \| Convertible Promissory Note
Debt Instrument [Line Items]
Principal amount		$ 35,000

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)	$ 20,166	$ (13,339)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Stock-based compensation	15,540	13,836
Interest on liability for sale of future royalties	12,720
Loss on extinguishment of debt	7,050
Depreciation and amortization	5,211	3,310
Write-off of inventory	1,909	3,659
Loss (gain) on available-for-sale securities	1,550	(932)
Loss on estimated returns of acquired product	1,444
Amortization of debt discount and issuance costs	1,333	1,570
Amortization of right-of-use assets	1,140	978
Loss (gain) on foreign currency transaction	526	(860)
Other, net	49	13
Sold portion of royalty revenue	(7,533)
Gain on bargain purchase	(5,259)
Net accretion of investments	(3,765)	(420)
Changes in operating assets and liabilities:
Accounts receivable, net	(3,728)	(5,021)
Inventory	(27)	(9,004)
Prepaid expenses and other current assets	(6,442)	(8,516)
Other assets	(2,821)	(35)
Accounts payable	(3,136)	5,702
Accrued expenses and other current liabilities	(4,809)	(3,824)
Deferred revenue	(7,211)	33,722
Recognized loss on purchase commitments	(2,689)	(6,810)
Operating lease liabilities	(1,407)	(1,778)
Net cash provided by operating activities	19,867	12,416
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of held-to-maturity debt securities	(273,789)	(50,516)
Proceeds from held-to-maturity debt securities	135,317	92,608
Purchase of property and equipment	(6,797)	(36,567)
Proceeds from insurance claim	396	382
Net cash (used in) provided by investing activities	(144,873)	5,907
CASH FLOWS FROM FINANCING ACTIVITIES:
Principal and early extinguishment payments on MidCap credit facility	(36,617)	(1,667)
Principal and early extinguishment payments on Mann Group convertible note	(8,854)
Payments for taxes related to net issuance of common stock associated with restricted stock units and stock options	(6,178)	(10,200)
Proceeds from market price stock purchase plan and employee stock purchase plan	2,320	1,075
Milestone payment	(752)	(924)
Principal payments on financing liability	(282)	(137)
Principal payments on financing lease liability	(3)
Net cash used in financing activities	(50,366)	(5,074)
NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH	(175,372)	13,249
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING OF PERIOD	238,480	69,767
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, END OF PERIOD	63,108	83,016
SUPPLEMENTAL CASH FLOWS DISCLOSURES:
Interest paid in cash	13,616	7,978
Income taxes paid in cash	1,961
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Assumption of right-of-use-asset and operating lease liability	10,057
Non-cash acquisition of intangible asset	4,300
Amortization of liability for sale of future royalties	2,912
Non-cash construction in progress, property and equipment	1,486	2,490
Non-cash acquisition of property and equipment	959
Addition of right-of-use-asset and financing lease liability	226
Right-of-use asset modification	0	728
Goodwill adjustment for a net reduction in liabilities		497
The Mann Group L L C
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Interest on Mann Group convertible note	56	165
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Payments of Mann Group principal and interest through common stock issuances	$ 3,806	165
At The Market Issuance
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from at-the-market offering		6,887
Issuance costs associated with at-the-market offering		$ (108)

Common and Preferred Stock - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended	3 Months Ended				9 Months Ended
	Feb. 28, 2018	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Class of Stock [Line Items]
Common stock, shares authorized						800,000,000		800,000,000
Common stock, par value						$ 0.01		$ 0.01
Undesignated preferred stock, shares authorized						10,000,000		10,000,000
Undesignated preferred stock, par value						$ 0.01		$ 0.01
Common stock, shares issued						275,775,038		270,034,495
Common stock, shares outstanding						275,775,038		270,034,495
Undesignated preferred stock, shares outstanding						0		0
Proceeds from market price stock purchase plan						$ 1.4	$ 0.2
Market price stock purchase plan						416,099	36,004
Common Stock
Class of Stock [Line Items]
Number of shares sold during the period		416,000	847,000	362,000	269,000
Controlled Equity Offering Sales Agreement \| Cantor Fitzgerald \| Common Stock \| Maximum
Class of Stock [Line Items]
Amount of net proceeds from issuance of securities	$ 50.0
At Market Issuance Sales Agreement \| Cantor Fitzgerald \| Common Stock
Class of Stock [Line Items]
Amount of net proceeds from issuance of securities						$ 6.9
Number of shares sold during the period						1,478,090
At Market Issuance Sales Agreement \| Cantor Fitzgerald \| Common Stock \| Weighted Average
Class of Stock [Line Items]
Exchange price per share						$ 4.66

Investments - Schedule of Fair Value of Cash Equivalents, Long and Short Term Investments (Detail) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Amortized Cost
Schedule Of Investments [Line Items]
Total cash equivalents and investments	$ 247,593	$ 122,418
Less: cash equivalents	(41,582)	(58,644)
Total Investments	206,011	63,774
Amortized Cost \| Money Market Funds \| Fair Value, Inputs, Level 1
Schedule Of Investments [Line Items]
Total cash equivalents and investments	31,298	69,611
Amortized Cost \| Commercial Bonds and Paper \| Fair Value, Inputs, Level 2
Schedule Of Investments [Line Items]
Total cash equivalents and investments	57,477	43,251
Amortized Cost \| U.S. Treasury Securities \| Fair Value, Inputs, Level 2
Schedule Of Investments [Line Items]
Total cash equivalents and investments	158,818	9,556
Gross Unrealized Holding Gains
Schedule Of Investments [Line Items]
Total cash equivalents and investments	968	191
Total Investments	968	191
Gross Unrealized Holding Gains \| Commercial Bonds and Paper \| Fair Value, Inputs, Level 2
Schedule Of Investments [Line Items]
Total cash equivalents and investments	268	135
Gross Unrealized Holding Gains \| U.S. Treasury Securities \| Fair Value, Inputs, Level 2
Schedule Of Investments [Line Items]
Total cash equivalents and investments	700	56
Gross Unrealized Holding Losses
Schedule Of Investments [Line Items]
Total cash equivalents and investments	(14)	(38)
Total Investments	(14)	(38)
Gross Unrealized Holding Losses \| Commercial Bonds and Paper \| Fair Value, Inputs, Level 2
Schedule Of Investments [Line Items]
Total cash equivalents and investments	(12)	(38)
Gross Unrealized Holding Losses \| U.S. Treasury Securities \| Fair Value, Inputs, Level 2
Schedule Of Investments [Line Items]
Total cash equivalents and investments	(2)
Estimated Fair Value
Schedule Of Investments [Line Items]
Total cash equivalents and investments	248,547	122,571
Less: cash equivalents	(41,582)	(58,644)
Total Investments	206,965	63,927
Estimated Fair Value \| Money Market Funds \| Fair Value, Inputs, Level 1
Schedule Of Investments [Line Items]
Total cash equivalents and investments	31,298	69,611
Estimated Fair Value \| Commercial Bonds and Paper \| Fair Value, Inputs, Level 2
Schedule Of Investments [Line Items]
Total cash equivalents and investments	57,733	43,348
Estimated Fair Value \| U.S. Treasury Securities \| Fair Value, Inputs, Level 2
Schedule Of Investments [Line Items]
Total cash equivalents and investments	$ 159,516	$ 9,612

Property and Equipment - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Property Plant And Equipment [Line Items]
Amount of divestiture of long-lived		$ 0		$ 0
Manufacturing Equipment
Property Plant And Equipment [Line Items]
Amount of divestiture of long-lived	$ 100,000		$ 100,000

Pulmatrix Transaction - Schedule of Fair Value of Identifiable Assets Acquired and Liabilities Assumed (Details) - Pulmatrix, Inc $ in Thousands	Jul. 08, 2024 USD ($)
Assets:
iSPERSE License - IPR&D	$ 4,300
Right-of-use asset - Bedford R&D facility	10,057
Property and equipment	959
Total assets	15,316
Liabilities:
Operating lease liability - Bedford R&D facility	10,057
Total liabilities	10,057
Net assets acquired - Gain on bargain purchase	$ 5,259

Collaboration, Licensing and Other Arrangements (Tables)

9 Months Ended

Sep. 30, 2024

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Schedule of Revenue from Collaboration and Services

Revenue from collaborations and services were as follows (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
UT CSA(1)	$	23,231	$	12,800	$	73,673	$	34,897
UT License Agreement (2)		—		271		347		698
Cipla License and Distribution Agreement		37		37		110		110
Total revenue from collaborations and services	$	23,268	$	13,108	$	74,130	$	35,705

_________________________

(1)

Amounts consist of revenue recognized for Manufacturing Services and Product Sales to UT for the periods presented.

(2)

Amounts consist of revenue recognized for Next-Gen R&D Services and R&D Services and License for the periods presented.

Schedule of Effect of Modification on Transaction Price

The Company determined that the capital and continuous improvements should be combined with the manufacturing services performance obligation and the alternative manufacturing processes should be combined with the Next-Gen R&D Services. The total revised anticipated cash flows of $722.3 million from the transaction was allocated to the three distinct performance obligations as follows (dollars in millions):

         
        Anticipated

         
        Cash Flow

        Revenue Allocation

        Recognition Method

        Progress Measure

        Revenue
Recognition

Total anticipated cash flow(1)

722.3

        Distinct Performance Obligation

R&D Services and License

—

Over time

Ratably

Aug 2021 - Oct 2021

Next-Gen R&D Services

10.0

Over time

Input

% of completion of costs

Manufacturing Services and
   Product Sales(2)

712.3

Point in time

Transfer of control

__________________________

(1)

(2)

United Therapeutics Corporation

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Schedule of Revenue from Collaboration and Services

Total revenue from UT was as follows (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
UT Revenue
UT CSA	$	23,231	$	12,800	$	73,673	$	34,897
UT License Agreement		—		271		347		698
Royalties – Collaboration (1)		27,083		20,218		75,326		50,951
Total revenue from UT	$	50,314	$	33,289	$	149,346	$	86,546

_________________________

(1)

Amounts consist of royalties associated with the UT License Agreement. The contract assets related to the royalties is included in prepaid expense and other current assets in the condensed consolidated balance sheets.

Goodwill and Other Intangible Assets (Tables)

9 Months Ended

Sep. 30, 2024

Goodwill And Intangible Assets Disclosure [Abstract]

Summary of Other Intangible Assets

Other Intangible Assets — Other intangible assets consisted of the following (dollars in thousands):


	Estimated		September 30, 2024							December 31, 2023
	Useful Life (Years)		Cost		Accumulated Amortization			Net Book Value		Cost		Accumulated Amortization			Net Book Value
Developed technology		15	$	1,200	$	(187	)	$	1,013	$	1,200	$	(127	)	$	1,073
iSPERSE License – IPR&D		—		4,300		—			4,300		—		—			—
Total			$	5,500	$	(187	)	$	5,313	$	1,200	$	(127	)	$	1,073

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenues:
Total revenues	$ 70,079	$ 51,253	$ 208,728	$ 140,490
Expenses:
Cost of goods sold	3,197	3,995	12,621	14,749
Research and development	12,926	9,989	34,755	22,047
Selling	13,093	13,440	36,189	40,752
General and administrative	10,823	10,538	34,168	33,027
Loss (gain) on foreign currency transaction	2,454	(2,065)	526	(860)
Total expenses	57,319	46,156	162,636	139,670
Income from operations	12,760	5,097	46,092	820
Other income (expense):
Interest income, net	3,179	1,580	9,790	4,429
Interest expense on liability for sale of future royalties	(4,089)		(12,720)
Interest expense on financing liability	(2,470)	(2,459)	(7,361)	(7,332)
Interest expense	(1,801)	(2,815)	(10,419)	(12,474)
Gain on bargain purchase	5,259		5,259
Other income	32	318	32	286
Loss on extinguishment of debt			(7,050)
(Loss) gain on available-for-sale securities			(1,550)	932
Total other expense	110	(3,376)	(24,019)	(14,159)
Income (loss) before income tax expense	12,870	1,721	22,073	(13,339)
Income tax expense	1,320		1,907
Net income (loss)	$ 11,550	$ 1,721	$ 20,166	$ (13,339)
Net income (loss) per share - basic	$ 0.04	$ 0.01	$ 0.07	$ (0.05)
Weighted average shares used to compute net income (loss) per share - basic	274,998	268,732	272,811	266,126
Net income (loss) per share - diluted	$ 0.04	$ 0.01	$ 0.07	$ (0.05)
Weighted average shares used to compute net income (loss) per share - diluted	284,693	323,770	281,407	266,126
Commercial product sales
Revenues:
Total revenues	$ 19,728	$ 17,927	$ 59,272	$ 53,834
Collaborations and services
Revenues:
Total revenues	23,268	13,108	74,130	35,705
Expenses:
Cost of revenue	14,826	10,259	44,377	29,955
Royalties
Revenues:
Total revenues	$ 27,083	$ 20,218	$ 75,326	$ 50,951

Description of Business and Significant Accounting Policies - Summary of Revenue and Cost of Revenue and Goods Sold Generated From Product Sales, Services and Royalties (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Disaggregation Of Revenue [Line Items]
Total net revenue	$ 70,079	$ 51,253	$ 208,728	$ 140,490
Total cost of goods sold and cost of revenue	18,023	14,254	56,998	44,704
Product Revenue
Disaggregation Of Revenue [Line Items]
Total net revenue	42,959	30,727	132,945	88,731
Total cost of goods sold and cost of revenue	18,023	13,983	56,651	44,006
Services
Disaggregation Of Revenue [Line Items]
Total net revenue	37	308	457	808
Total cost of goods sold and cost of revenue	0	271	347	698
Royalties
Disaggregation Of Revenue [Line Items]
Total net revenue	$ 27,083	$ 20,218	$ 75,326	$ 50,951

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References + Details

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-4

+ Details

Commitment and contingencies - Schedule of Remaining Financing Lease Payments (Detail) $ in Thousands	Sep. 30, 2024 USD ($)
Commitments And Contingencies [Line Items]
Remainder of 2024	$ 2,532
2025	10,269
2026	10,533
2027	10,849
2028	11,174
Thereafter	177,278
Total	222,635
Interest payments	(116,113)
Total financing liability	104,003
Audio Visual Equipment
Commitments And Contingencies [Line Items]
Remainder of 2024	27
2025	54
2026	54
2027	54
2028	54
Thereafter	23
Total	266
Interest payments	(43)
Total financing liability	$ 223

Earnings Per Common Share (Tables)

9 Months Ended

Sep. 30, 2024

Earnings Per Share [Abstract]

Components of Basic and Diluted EPS Computations

The following tables summarize the components of the basic and diluted EPS computations (in thousands, except per share amounts):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
EPS — basic:
Net income (loss) (numerator)	$	11,550	$	1,721	$	20,166	$	(13,339	)
Weighted average common shares (denominator)		274,998		268,732		272,811		266,126
Net income (loss) per share	$	0.04	$	0.01	$	0.07	$	(0.05	)
EPS — diluted:
Adjusted net income (loss) (numerator)	$	11,550	$	3,578	$	20,166	$	(13,339	)
Weighted average common shares		274,998		268,732		272,811		266,126
Effect of dilutive securities — common shares issuable		9,695		55,038		8,596		—
Adjusted weighted average common shares (denominator)		284,693		323,770		281,407		266,126
Net income (loss) per share	$	0.04	$	0.01	$	0.07	$	(0.05	)

Potential Dilutive Securities Outstanding that are Considered Antidilutive

Potentially dilutive securities outstanding which were considered antidilutive due to the net losses incurred for the nine months ended September 30, 2023 are summarized as follows (in shares):


	September 30,
	2023
Senior convertible notes		44,120,463
RSUs and Market RSUs(1)		21,151,454
Common stock options and PNQs		8,447,339
Mann Group convertible notes		3,370,000
Total shares		77,089,256

__________________________

(1)

Market RSUs issued in 2021, 2022 and 2023 are included at the share delivery of 0%, 205% and 219%, respectively, in accordance with a valuation assessment obtained as of September 30, 2023.

Stock-Based Compensation Expense - Additional Information (Detail) - USD ($)	3 Months Ended				9 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Sep. 30, 2024
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Issuance of common stock under the employee stock purchase plan		$ 959,000		$ 923,000
Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Issuance of common stock under the employee stock purchase plan		$ 3,000		$ 3,000
Issuance of common stock under the employee stock purchase plan (in shares)		310,000		266,000
ESPP
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock available for issuance	2,600,000				2,600,000
Employees Awards
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Issuance of common stock under the employee stock purchase plan					$ 25,000
Issuance of common stock under the employee stock purchase plan (in shares)					5,000
Employees Awards \| ESPP
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Discount on purchase price percentage of fair market value					85.00%
RSUs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted stock units weighted average grant date fair value	$ 5.3	$ 4.45	$ 3.28
Restricted stock units grant date fair value	219,285	3,033,680	211,895
Unrecognized compensation expense, weighted average period for recognition					2 years 10 months 2 days
Unrecognized compensation expense related to non-option	$ 26,200,000				$ 26,200,000
RSUs \| Share-Based Payment Arrangement, Tranche One
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period		4 years	3 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	33.30%	25.00%	33.30%
RSUs \| Share-Based Payment Arrangement, Tranche Two
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period		2 years	4 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	33.30%	33.30%	33.30%
RSUs \| Share-Based Payment Arrangement, Tranche Three
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	33.30%	33.30%	33.30%
RSUs \| Employees Awards \| Share-Based Payment Arrangement, Tranche One
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period	2 years	2 years	2 years
Restricted stock units grant date fair value	21,968	145,980	53,720
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	40.00%
RSUs \| Employees Awards \| Share-Based Payment Arrangement, Tranche Two
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period	3 years	3 years	3 years
Restricted stock units grant date fair value		26,250	2,375
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	60.00%		25.00%
RSUs \| Employees Awards \| Share-Based Payment Arrangement, Tranche Three
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period	4 years	4 years	4 years
Market RSU's
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted stock units weighted average grant date fair value		$ 10.3
Unrecognized compensation expense, weighted average period for recognition					1 year 11 months 23 days
Unrecognized compensation expense related to non-option	$ 27,400,000				$ 27,400,000
Market RSU's \| Employees Awards \| Share-Based Payment Arrangement, Tranche One
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		0.00%
Market RSU's \| Employees Awards \| Share-Based Payment Arrangement, Tranche Two
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		50.00%
Market RSU's \| Employees Awards \| Share-Based Payment Arrangement, Tranche Three
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		100.00%

Borrowings - Schedule of Amortization of Premium and Accretion of Debt Issuance Costs (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Debt Disclosure [Abstract]
Amortization of debt discount and prepayment fee		$ 109	$ 85	$ 323
Amortization of debt issuance cost	$ 363	$ 363	$ 1,175	$ 1,090

Commitments and Contingencies - Schedule of Remaining Financing Liability Payments (Detail) $ in Thousands	Sep. 30, 2024 USD ($)
Operating Lease Liabilities Payments Due [Abstract]
Remainder of 2024	$ 2,532
2025	10,269
2026	10,533
2027	10,849
2028	11,174
Thereafter	177,278
Total	222,635
Interest payments	(116,113)
Debt issuance costs	(2,519)
Total financing liability	$ 104,003

Investments - Additional Information (Detail)	3 Months Ended		9 Months Ended
Investments - Additional Information (Detail)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($) Note	Sep. 30, 2023 USD ($)	Jun. 30, 2024 USD ($)	Dec. 31, 2023 USD ($)
Schedule Of Investments [Line Items]
Interest on held to maturity investments	$ 3,200,000	$ 1,500,000	$ 9,800,000	$ 4,000,000
Net accretion on investments held to maturity	2,100,000	500,000	6,000,000	900,000
Allowance for credit losses	0		0			$ 0
Prepaid Expenses and Other Current Assets
Schedule Of Investments [Line Items]
Accrued interest receivable	$ 1,100,000		$ 1,100,000			$ 500,000
Convertible Promissory Note \| Thirona Bio, Inc.
Schedule Of Investments [Line Items]
Hypothetical yield percentage	28		28			35
Volatility percentage	70		70			90
Interest on available for sale investment	$ 0	100,000	$ 0	400,000
Number of notes \| Note			2
Amount Due	$ 8,000,000		$ 8,000,000		$ 8,000,000
Stated interest rate	10.00%		10.00%
Investment securities	$ 5,900,000		$ 5,900,000			$ 6,900,000
Recognized gain (loss)		900,000	1,600,000	900,000
Unrealized holding gain		$ 400,000	$ 600,000	$ 400,000

Income Taxes - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended	9 Months Ended
	Jun. 30, 2024	Sep. 30, 2024	Sep. 30, 2024
Operating Loss Carryforwards [Line Items]
Income tax expense		$ 1,320,000	$ 1,907,000
Effective tax rate (as a percent)			21.00%
Unrecognized income tax interest and penalties			$ 0
California \| Senate Bills 167
Operating Loss Carryforwards [Line Items]
Net operating losses	$ 5,000,000
Tax years	2024 2025 2026
California \| Senate Bills 175
Operating Loss Carryforwards [Line Items]
Tax years	2025 2026

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-10

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Subparagraph (a)
-SubTopic 20
-Topic 740
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482659/740-20-45-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-SubTopic 10
-Topic 235
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

+ Details

Accounts Receivable

9 Months Ended

Sep. 30, 2024

Receivables [Abstract]

Accounts Receivable

4. Accounts Receivable

Accounts receivable, net consists of the following (in thousands):


	September 30, 2024			December 31, 2023
Accounts receivable – commercial
Accounts receivable, gross	$	18,359		$	20,199
Wholesaler distribution fees and prompt pay discounts		(2,363	)		(2,469	)
Reserve for returns		(7,817	)		(6,215	)
Allowance for credit losses		—			(157	)
Total accounts receivable – commercial, net		8,179			11,358
Accounts receivable – collaborations and services		10,005			3,543
Total accounts receivable, net	$	18,184		$	14,901

As of December 31, 2023, the allowance for credit losses and doubtful accounts for commercial accounts receivable of $0.2 million was related to accounts receivable for Zealand Pharma US, Inc. As of September 30, 2024, the Company had three wholesale distributors representing approximately 87% of commercial accounts receivable and 77% and 73% of gross sales during the three and nine months ended September 30, 2024, respectively.

As of September 30, 2024 and December 31, 2023, there was no allowance for credit losses for accounts receivable for collaborations and services. The Company had one collaboration partner, UT, that comprised 100% of the collaboration and services net accounts receivable as of September 30, 2024 and December 31, 2023 and approximately 100% of gross revenue from collaborations and services for the three and nine months ended September 30, 2024.

Commitments and Contingencies - Additional Information (Detail)
€ in Millions

1 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

Jul. 31, 2024

USD ($)

Jun. 30, 2024

USD ($)

Dec. 31, 2023

USD ($)

ConsecutiveMonth

Feb. 28, 2023

USD ($)

Jun. 30, 2022

USD ($)

Nov. 30, 2021

USD ($)

Sep. 30, 2024

USD ($)

Sep. 30, 2023

USD ($)

Sep. 30, 2024

USD ($)

Sep. 30, 2023

USD ($)

Dec. 31, 2023

USD ($)

Sep. 30, 2024

EUR (€)

Sep. 30, 2024

USD ($)

Jul. 08, 2024

Jul. 01, 2013

USD ($)

Commitments And Contingencies [Line Items]

Operating lease costs

$ 719,000

$ 422,000

$ 1,417,000

$ 1,253,000

Operating lease weighted average discount rate

7.25%

Financing Liability

$ 104,100,000

$ 104,000,000

Financing liability - long term

94,319,000

94,005,000

Financing liability - current

9,809,000

9,998,000

Supply Agreement expiration period

Dec. 31, 2034

Supply Agreement renewal period

2 years

Lease monthly payments

$ 100,000

Percentage of annual increment on lease

3.00%

Milestone liabilities

3,452,000

2,813,000

Returns reserve for acquired product

^[1]

601,000

1,468,000

Losses on estimated returns of acquired product

$ 1,400,000

Milestone payments

752,000

924,000

Loss on purchase commitments | €

€ 56.6

Insulin

Commitments And Contingencies [Line Items]

Loss on purchase commitments

$ 64,800,000

64,800,000

62,600,000

Tyvaso DPI

Commitments And Contingencies [Line Items]

Royalty commencement date

Oct. 01, 2023

Royalty termination date

Dec. 31, 2042

Pulmatrix, Inc

Commitments And Contingencies [Line Items]

Lease renewal option

5 years

Landlord-funded tenant improvements payable

$ 700,000

Landlord-funded tenant improvements payable per month

6,000,000,000

Lease monthly payments

$ 101,282

Percentage of annual increment on lease

3.00%

Equipment | V-Go

Commitments And Contingencies [Line Items]

Lease Cost

$ 14,370

Master Lease Agreement with Enterprise | Vehicle Leases

Commitments And Contingencies [Line Items]

Operating lease rent expenses

$ 100,000

Marlborough Lease | Buildings

Commitments And Contingencies [Line Items]

Operating lease rent expenses

$ 28,895

Percentage of annual increase in lease payment

3.00%

Casper L L C

Commitments And Contingencies [Line Items]

Sale price

$ 102,300,000

Lease initial term

20 years

Lease renewal options

renewal options of five years

Lessee,option to extend [true false]

true

Operating lease costs

$ 9,500,000

Operating lease weighted average discount rate

9.00%

Lease, description

The total annual rent under the Lease starts at approximately $9.5 million per year, subject to a 50% rent abatement during the first year of the Lease, and will increase annually by (i) 2.5% in the second through fifth year of the Lease and (ii) 3% in the sixth and each subsequent year of the Lease, including any renewal term, utilizing a weighted average discount rate of 9.0%.

Security deposit

$ 2,000,000.0

Lease repurchase description

the Company has four options to repurchase the Property, in 2026, 2031, 2036 and 2041, for the greater of (i) $102.3 million and (ii) the fair market value of the Property.

Maximum

Commitments And Contingencies [Line Items]

Effective interest rate

11.50%

Minimum

Commitments And Contingencies [Line Items]

Effective interest rate

8.80%

Minimum | Casper L L C

Commitments And Contingencies [Line Items]

Lease repurchase, amount

$ 102,300,000

Deerfield | Milestone Rights Liability

Commitments And Contingencies [Line Items]

Contingent liability remain payable

$ 50,000,000

Remaining milestone rights liability

$ 3,200,000

$ 3,900,000

3,900,000

Milestone rights liability, current

800,000

700,000

Milestone liabilities

3,100,000

$ 2,500,000

Milestone payments

$ 5,000,000

Deerfield | Milestone Rights Liability | Maximum

Commitments And Contingencies [Line Items]

Contingent liability for milestone payments

$ 90,000,000

Russell Ranch Road II LLC | Office Lease

Commitments And Contingencies [Line Items]

Operating lease rent expenses

$ 79,543

Percentage of annual increase in lease payment

3.00%

Description of right to extension of lease term

The Company has no further right to extend the lease term beyond July 31, 2028.

Russell Ranch Road II LLC | Maximum | Office Lease

Commitments And Contingencies [Line Items]

Reimbursement for tenant improvements

$ 900,000

Additional base rent concession

$ 700,000

Sagard

Commitments And Contingencies [Line Items]

Upfront proceeds

150,000,000

Reimbursements

$ 400,000

Percentage of royalty on future net sales

1.00%

Unamortized transaction costs

$ 4,200,000

$ 4,400,000

Sagard | Tyvaso DPI

Commitments And Contingencies [Line Items]

Purchase price

$ 200,000,000

Sagard | Net Sales Threshold A | Tyvaso DPI

Commitments And Contingencies [Line Items]

Milestone payments

50,000,000

Net sales

1,900,000,000

Sagard | Net Sales Threshold B | Tyvaso DPI

Commitments And Contingencies [Line Items]

Milestone payments

45,000,000

Net sales

$ 2,300,000,000

Number of consecutive months | ConsecutiveMonth

Sagard | Net Sales Thresholds A and B | Tyvaso DPI

Commitments And Contingencies [Line Items]

Net sales

$ 3,500,000,000

Sagard | Remainder of Year

Commitments And Contingencies [Line Items]

Royalties

$ 0

Sagard | Royalty Liability

Commitments And Contingencies [Line Items]

Royalty rights

1.00%

Transaction costs

$ 4,400,000

Percentage of Future Royalty Revenues

10.00%

[1]	See Note 15 – Commitments and Contingencies under Loss Contingencies — Returns Reserve for Acquired Product.

Stock-Based Compensation Expense - Stock Based Compensation Expense Recognized in Condensed Consolidated Statements of Operations (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total	$ 5,227	$ 4,601	$ 15,540	$ 13,836
RSUs and Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total	5,047	4,442	14,994	13,324
Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total	$ 180	$ 159	$ 546	$ 512

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

+ Details

Inventories - Components of Inventory (Detail) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Inventory Disclosure [Abstract]
Raw materials	$ 6,437	$ 6,262
Work-in-process	9,074	13,646
Finished goods	11,152	8,637
Total inventory	$ 26,663	$ 28,545

Goodwill and Other Intangible Assets - Additional Information (Detail) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Finite Lived Intangible Assets [Line Items]
Goodwill	$ 1,931	$ 1,931
Developed Technology
Finite Lived Intangible Assets [Line Items]
2024	100
2025	100
2026	100
2027	100
2028	100
After 2028	$ 600

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References + Details

- Definition

Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 49
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-49

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482548/350-20-55-24

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 100
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-100

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(15))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482598/350-20-45-1

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(10)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

+ Details

Commitments and Contingencies - Schedule of Future Minimum Office And Vehicle Lease Payments (Detail) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Commitments And Contingencies [Line Items]
Operating lease, liability	$ 14,598	$ 5,348
office and vehicle
Commitments And Contingencies [Line Items]
Remainder of 2024	784
Year 1	3,157
Year 2	2,579
Year 3	2,540
Year 4	2,087
Thereafter	7,721
Total	18,868
Interest expense	(4,270)
Operating lease, liability	$ 14,598

Description of Business and Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2024

Accounting Policies [Abstract]

Business

Business — MannKind is a biopharmaceutical company focused on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. The Company’s signature technologies—Technosphere dry-powder formulations and Dreamboat inhalation devices—offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation. The Company is currently commercializing Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin. The first product to come out of the orphan lung disease pipeline, Tyvaso DPI (treprostinil) inhalation powder, received approval from the U.S. Food and Drug Administration (“FDA”) in May 2022 for the treatment of pulmonary arterial hypertension (“PAH”) and for the treatment of pulmonary hypertension associated with interstitial lung disease (“PH-ILD”). The Company's development and marketing partner, UT, began commercializing Tyvaso DPI in June 2022 and is obligated to pay a 10% royalty on net sales of the product, of which 9% is allocated to the Company and 1% to another party as detailed in Note 15 – Commitments and Contingencies. The Company also receives a margin on supplies of Tyvaso DPI that it manufactures for UT.

Basis of Presentation

Basis of Presentation — The condensed consolidated financial statements have been prepared in accordance with GAAP.

Principles of Consolidation

Principles of Consolidation — The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. Intercompany balances and transactions have been eliminated.

Reclassifications

Reclassifications — Certain amounts reported in the prior period have been reclassified to conform with current period presentation. The Company has separated non-cash accretion income on investments from other, net, and presented it as net accretion of investments in the condensed consolidated statements of cash flows. The Company has also presented non-cash interest accretion on financing liability in other, net. Additionally, the Company has combined accruals for the Danbury facility buildout with other in Note 8 – Accrued Expenses and Other Current Liabilities.

Segment Information

Segment Information — Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. To date, the Company has viewed its operations and manages its business as one segment operating in the United States of America ("U.S.").

Revenue Recognition

Revenue Recognition — The Company recognizes revenue when its customers obtain control of promised goods or services, in an amount that reflects the consideration which the Company expects to be entitled in exchange for those goods or services.

To determine revenue recognition for arrangements that are within the scope of Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”), the Company performs the following five steps: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to arrangements that meet the definition of a contract under ASC 606, including when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer.

At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company has two types of contracts with customers: (i) contracts for commercial product sales with wholesale distributors, specialty and retail pharmacies, and durable medical equipment suppliers ("DMEs") and (ii) collaboration arrangements.

Revenue Recognition - Net Revenue - Commercial Product Sales

Revenue Recognition — Net Revenue — Commercial Product Sales — The Company sells its products to a limited number of wholesale distributors, specialty and retail pharmacies, and DMEs in the U.S. (collectively, its “Customers”). Wholesale distributors subsequently resell the Company’s products to retail pharmacies and certain medical centers or hospitals. Specialty and retail pharmacies sell directly to patients. In addition to distribution agreements with Customers, the Company enters into arrangements with payers that provide for government mandated and/or privately negotiated rebates, chargebacks, and discounts with respect to the purchase of the Company’s products.

The Company transfers control and recognizes revenue upon delivery of product to wholesale distributors and specialty pharmacies. The Company transfers control and recognizes revenue on product sales to a retail pharmacy as the product is dispensed to patients. Product revenues are recorded net of applicable reserves, including discounts, allowances, rebates, returns and other incentives. See Reserves for Variable Consideration below.

Reserves for Variable Consideration — Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established. Components of variable consideration include trade discounts and allowances, product returns, provider chargebacks and discounts, government rebates, payer rebates, and other incentives, such as voluntary patient assistance, and other allowances that are offered within contracts between the Company and its Customers, payers, and other indirect customers relating to the Company’s sale of its products. These reserves, as further detailed below, are based on the amounts earned, or to be claimed on the related sales, and result in a reduction of accounts receivable or establishment of a current liability. Significant judgment is required in estimating gross-to-net adjustments, including historical experience, payer channel mix, current contract prices under applicable programs, unbilled claims, claim submission time lags and inventory levels in the distribution channel.

Where appropriate, these estimates take into consideration a range of possible outcomes, which are probability-weighted in accordance with the expected value method in ASC 606 for relevant factors such as current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. Overall, these reserves reduce recognized revenue to the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the respective underlying contracts.

The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. The Company’s analysis also contemplates application of the constraint in accordance with the guidance, under which it determined a material reversal of revenue would not occur in a future period for the current period estimates of gross-to-net adjustments and, therefore, the transaction price was not reduced further during the current period. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results in the future vary from the Company’s estimates, the Company will adjust these estimates, which would affect net revenue from commercial product sales and earnings in the period such variances become known.

Trade Discounts and Allowances — The Company generally provides Customers with discounts which include incentives, such as prompt pay discounts, that are explicitly stated in the Company’s contracts and are recorded as a reduction of revenue in the period the

related product revenue is recognized. In addition, the Company compensates (through trade discounts and allowances) its Customers for sales order management, data, and distribution services. However, the Company has determined such services received to date are not distinct from the Company’s sale of products to the Customer and, therefore, these payments have been recorded as a reduction of revenue and as a reduction to accounts receivable, net.

Product Returns — Consistent with industry practice, the Company generally offers Customers a right of return for unopened product that has been purchased from the Company for a period beginning six months prior to and ending 12 months after its expiration date, which lapses upon shipment to a patient. The Company estimates the amount of its product sales that may be returned by its Customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized, as well as reductions to accounts receivable, net. The Company currently estimates product returns using available industry data and its own sales information, including its visibility into the inventory remaining in the distribution channel. The Company’s current return reserve percentage is estimated to be in the single digits. Adjustments to the returns reserve are made when changes in the Company's assumptions result in revised estimates.

Provider Chargebacks and Discounts — Chargebacks for fees and discounts to providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to Customers who directly purchase products from the Company. Customers charge the Company for the difference between what they pay for products and the ultimate selling price to the qualified healthcare providers. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability that is recorded in accrued expenses and other current liabilities. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by Customers, and the Company generally issues credits for such amounts within a few weeks of the Customer’s notification to the Company of the resale. Reserves for chargebacks consist of credits that the Company expects to issue for units that remain in the distribution channel inventories at each reporting period-end that the Company expects will be sold to qualified healthcare providers, and chargebacks that Customers have claimed, but for which the Company has not yet issued a credit.

Government Rebates — The Company is subject to discount obligations under Medicare and state Medicaid programs. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability that is included in accrued expenses and other current liabilities. Estimates around Medicaid have historically required significant judgment due to timing lags in receiving invoices for claims from states. For Afrezza, the Company also estimates the number of patients in the prescription drug coverage gap for whom the Company will owe an additional liability under the Medicare Part D program. The Company’s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated future claims that will be made for products that have been recognized as revenue, but which remains in the distribution channel inventories at the end of each reporting period. The Company’s estimates include consideration of historical claims experience, payer channel mix, current contract prices, unbilled claims, claim submission time lags and inventory in the distribution channel.

Payer Rebates — The Company contracts with certain private payer organizations, primarily insurance companies and pharmacy benefit managers, for the payment of rebates with respect to utilization of its products. The Company estimates these rebates, including estimates for product that has been recognized as revenue, but which remains in the distribution channel, and records such estimates in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses and other current liabilities. The Company’s estimates include consideration of historical claims experience, payer channel mix, current contract prices, unbilled claims, claim submission time lags and inventory in the distribution channel.

Other Incentives — Other incentives which the Company offers include voluntary patient support programs, such as the Company's co-pay assistance program, which are intended to provide financial assistance to qualified commercially-insured patients with co-payments required by payers. The calculation of the accrual for co-pay assistance is based on an estimate of claims and the cost per claim that the Company expects to receive associated with the products that have been recognized as revenue but remains in the distribution channel inventories at the end of each reporting period. The adjustments are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability that is included in accrued expenses and other current liabilities.

Revenue Recognition- Net Revenue - Collaborations and Services

Revenue Recognition — Revenue — Collaborations and Services — The Company enters into licensing, research or other agreements under which the Company licenses certain rights to its product candidates to third parties, conducts research or provides other services to third parties. The terms of these arrangements may include but are not limited to payment to the Company of one or more of the following: up-front license fees; development, regulatory, and commercial milestone payments; payments for commercial manufacturing and clinical supply services the Company provides; and royalties on net sales of licensed products and sublicenses of the rights. As part of the accounting for these arrangements, the Company must develop assumptions that require judgment such as determining the performance obligation in the contract and determining the stand-alone selling price for each performance obligation identified in the contract. With respect to the Company's significant collaboration and service agreement with UT that includes a long-term commercial supply agreement (as amended, the “CSA”), the Company has identified three distinct performance obligations: (1) the license, supply of product to be used in clinical development, and continued development and approval support for Tyvaso DPI (“R&D Services and License”); (2) development activities for the next generation of the product (“Next-Gen R&D Services”); and (3) a material right associated with current and future manufacturing and supply of product (“Manufacturing Services and Product Sales”). Pre-production activities under the CSA, such as facility expansion services and other administrative services, were considered bundled services under the Manufacturing Services and Product Sales performance obligation as required by ASC 606. Following the FDA’s approval of Tyvaso DPI, UT began issuing purchase orders for the supply of product, which represents distinct contracts and performance obligations under ASC 606. Revenue is recognized for the supply of product at a point in time, once control is transferred to UT. See Note 10 – Collaboration, Licensing and Other Arrangements.

If an arrangement has multiple performance obligations, the allocation of the transaction price is determined from observable market inputs, and the Company uses key assumptions to determine the stand-alone selling price, which may include development timelines, reimbursement rates for personnel costs, discount rates, and probabilities of technical and regulatory success. Revenue is recognized based on the measurement of progress as the performance obligation is satisfied and consideration received that does not meet the requirements to satisfy the revenue recognition criteria is recorded as deferred revenue. Current deferred revenue consists of amounts that are expected to be recognized as revenue in the next 12 months. Amounts that the Company expects will not be recognized within the next 12 months are classified as long-term deferred revenue. For further information, see Note 10 – Collaboration, Licensing and Other Arrangements.

The Company recognizes upfront license payments as revenue upon delivery of the license only if the license is determined to be a separate unit of accounting from the other undelivered performance obligations. The undelivered performance obligations typically include manufacturing or development services or research and/or steering committee services. If the license is not considered as a distinct performance obligation, then the license and other undelivered performance obligations would be evaluated to determine if such should be accounted for as a single unit of accounting. If concluded to be a single performance obligation, the transaction price for the single performance obligation is recognized as revenue over the estimated period of when the performance obligation is satisfied. If the license is considered to be a distinct performance obligation, then the estimated revenue is included in the transaction price for the contract, which is then allocated to each performance obligation based on the respective standalone selling prices.

Whenever the Company determines that an arrangement should be accounted for over time, the Company determines the period over which the performance obligations will be performed, and revenue will be recognized over the period the Company is expected to complete its performance obligations. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations under an arrangement.

The Company’s collaboration agreements typically entitle the Company to additional payments upon the achievement of development, regulatory and sales milestones. If the achievement of a milestone is considered probable at the inception of the collaboration, the related milestone payment is included with other collaboration consideration, such as upfront fees and research funding, in the Company’s revenue calculation. If these milestones are not considered probable at the inception of the collaboration, the milestones will typically be recognized in one of two ways depending on the timing of when the milestone is achieved. If the milestone is improbable at inception and subsequently deemed probable of achievement, such will be added to the transaction price, resulting in a cumulative adjustment to revenue. If the milestone is achieved after the performance period has been completed and all performance obligations have been delivered, the Company will recognize the milestone payment as revenue in its entirety in the period the milestone was achieved.

The Company’s collaboration agreements, for accounting purposes, represent contracts with customers and therefore are not subject to accounting literature on collaboration agreements. The Company grants licenses to its intellectual property, supplies raw materials, semi-finished goods or finished goods, provides research and development services and offers sales support for the co-promotion of products, all of which are outputs of the Company’s ongoing activities, in exchange for consideration. Accordingly, the Company concluded that its collaboration agreements must generally be accounted for pursuant to ASC 606.

For collaboration agreements that allow collaboration partners to select additional optioned products or services, the Company evaluates whether such options contain material rights (i.e., have exercise prices that are discounted compared to what the Company

would charge for a similar product or service to a new collaboration partner). The exercise price of these options includes a combination of licensing fees, event-based milestone payments and royalties. When these amounts in aggregate are not offered at a discount that exceeds discounts available to other customers, the Company concludes the option does not contain a material right, and therefore is not included in the transaction price at contract inception. The Company assessed the long-term commercial supply agreement with UT (as amended, the "CSA") and determined that a material right existed for the manufacturing services performance obligation. The transaction price is allocated to the material right as well as the remaining performance obligations in accordance with ASC 606. The Company also evaluates grants of additional licensing rights upon option exercises to determine whether such should be accounted for as separate contracts.

Revenue Recognition — Royalties — The Company recognizes royalty revenue for a sales-based or usage-based royalty if it is promised in exchange for an intellectual property license. The royalty revenue is recognized as the latter of the subsequent sale of the product occurs or if the performance obligation to which the royalty has been allocated has been satisfied or partially satisfied. The Company’s UT License Agreement (as defined in Note 10 – Collaboration, Licensing and Other Arrangements) entitles it to receive a 10% royalty on net sales of Tyvaso DPI for the license of the Company’s IP that was considered to be interdependent with the development activities that supported the approval of Tyvaso DPI. Although the Company recognizes a 10% royalty on net revenue from the sale of Tyvaso DPI as revenue, it only collects 9% due to its sale in December 2023 of 1% of future royalties as detailed in Note 15 – Commitments and Contingencies.


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Net revenue:
Product revenue (1)	$	42,959	$	30,727	$	132,945	$	88,731
Services (2)		37		308		457		808
Royalties (3)		27,083		20,218		75,326		50,951
Total net revenue	$	70,079	$	51,253	$	208,728	$	140,490

_________________________

(1)

Amounts represent the revenue from Afrezza and V-Go sales to wholesalers and specialty pharmacies and Tyvaso DPI to UT.

(2)

(3)

Amounts represent royalties on UT’s net revenue from Tyvaso DPI sales.


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Cost of goods sold and cost of revenue:
Product revenue	$	18,023	$	13,983	$	56,651	$	44,006
Services		—		271		347		698
Total cost of goods sold and cost of revenue	$	18,023	$	14,254	$	56,998	$	44,704

The Company follows accounting guidance in measuring revenue and certain judgments affect the application of its revenue policy. For example, in connection with its existing collaboration agreements, the Company has recorded short-term and long-term deferred revenue on its condensed consolidated balance sheets based on its best estimate of when such revenue will be recognized. Short-term deferred revenue consists of amounts that are expected to be recognized as revenue in the next 12 months. Amounts that the Company expects will not be recognized within the next 12 months are classified as long-term deferred revenue. However, this estimate is based on the Company’s current project development plan and, if the development plan should change in the future, the Company may recognize a different amount of deferred revenue over the next 12-month period.

Milestone Payments

Milestone Payments — At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the customer, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as, or when, the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company will re-evaluate the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its

estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration, other revenue, and earnings in the period of adjustment.

Cost of Goods Sold

Cost of Goods Sold — Cost of goods sold includes material, labor costs and manufacturing overhead. Cost of goods sold also includes a component of current period manufacturing costs in excess of costs capitalized into inventory (“excess capacity costs”). These costs, in addition to the impact of the revaluation of inventory for standard costing, and write-offs of inventory are recorded as expenses in the period in which they are incurred, rather than as a portion of inventory costs. Cost of goods sold excludes the cost of insulin purchased under the Company’s Insulin Supply Agreement (the “Insulin Supply Agreement”) with Amphastar Pharmaceuticals, Inc. (“Amphastar”). All insulin inventory on hand was written off and the full purchase commitment contract to purchase future insulin was accrued as a recognized loss on purchase commitments as of the end of 2016.

Cost of Revenues

Cost of Revenues — Collaborations and Services — Cost of revenues for collaborations and services includes material, labor costs, manufacturing overhead, and excess capacity costs. These costs, in addition to the write-offs of inventory are recorded as expenses in the period in which they are incurred, rather than as a portion of inventory costs. Cost of revenues for collaborations and services also includes the cost of product development.

Research and Development

Research and Development ("R&D") — Clinical trial expenses result from obligations under contracts with vendors, consultants and clinical site agreements in addition to internal costs associated with conducting clinical trials. R&D costs are expensed as incurred. Clinical study and certain research costs are recognized over the service periods specified in the contracts and adjusted as necessary based upon an ongoing review of the level of effort and costs actually incurred. Nonrefundable advance payments for services to be received in the future for use in R&D activities are recorded as prepaid assets and expensed in the period when the services are performed.

Cash, Cash Equivalents and Restricted Cash

Cash, Cash Equivalents and Restricted Cash — The Company considers all highly liquid investments with original or remaining maturities of 90 days or less at the time of purchase that are readily convertible into cash to be cash equivalents. As of September 30, 2024 and December 31, 2023, cash equivalents were comprised of money market funds, U.S. Treasury securities, corporate bonds and commercial paper with original maturities less than 90 days from the date of purchase.

The Company records restricted cash when cash and cash equivalents are restricted as to withdrawal or usage. Restricted cash under a letter of credit issued in connection with a facility lease assumed by the Company that will not be available for use in the Company’s operations within 12 months of the reporting date is presented in non-current assets. See Note 2 – Pulmatrix Transaction.

Held-to-Maturity Investments

Held-to-Maturity Investments — The Company’s investments generally consist of commercial paper, corporate notes or bonds and U.S. Treasury securities. As of September 30, 2024 and December 31, 2023, the Company held short-term and long-term investments of debt securities, including commercial paper and bonds. The Company intends to hold its investments until maturity; therefore, these investments are stated at amortized cost. The investments with maturities less than 12 months are included in short-term investments and investments with maturities in excess of twelve months are included in long-term investments in the condensed consolidated balance sheets. The amortization or accretion of the Company’s investments is recognized as interest income in the condensed consolidated statements of operations.

Available-for-Sale Investment

Available-for-Sale Investment — In June 2021, the Company purchased a $3.0 million convertible promissory note issued by Thirona Bio, Inc. (“Thirona”). In January 2022, the Company purchased an additional $5.0 million convertible promissory note issued by Thirona (the “Thirona convertible notes”). The Thirona convertible notes are general unsecured obligations of Thirona and initially accrued interest at a rate of 6% per annum. Unless earlier converted into conversion shares pursuant to the note purchase agreement, the aggregate principal of $8.0 million and accrued interest shall be due and payable by Thirona on demand by the Company at any time after the maturity date. The Thirona convertible notes were amended in February 2023 to extend the maturity date from December 31, 2022 to June 30, 2024, and again on June 27, 2024 to extend the maturity date to June 30, 2026 and increase the interest rate to 10% per annum.

The Thirona convertible notes are classified as available-for-sale securities and included in other assets as of September 30, 2024 and prepaid expense and other current assets as of December 31, 2023 in the condensed consolidated balance sheets. The Company periodically assesses whether it has any intention to sell the investment, determines the fair value of its available-for-sale investment using level 3 inputs and assesses whether there were other-than-temporary impairments associated with the investment. Unrealized holding gains and losses are excluded from earnings and reported in other comprehensive income until realized, while unrealized losses related to credit risk are reported through earnings in the period incurred.

Concentration of Credit Risk

Concentration of Credit Risk — Financial instruments that potentially subject the Company to concentration of credit risk consisted of cash and cash equivalents and investments. Cash and cash equivalents are held in high credit quality institutions. Cash equivalents consisted of interest-bearing money market funds and U.S. Treasury securities with original or remaining maturities of 90 days or less

at the time of purchase. Investments generally consisted of commercial paper, corporate notes or bonds and U.S. Treasury securities. The cash equivalents and investments are regularly monitored by management.

Accounts Receivable and Allowance for Credit Losses

Accounts Receivable and Allowance for Credit Losses — Accounts receivable are recorded at the invoiced amount and are not interest bearing. Accounts receivable are presented net of an allowance for credit losses if there are estimated losses resulting from the inability of its customers to make required payments. The Company makes ongoing assumptions relating to the collectability of its accounts receivable in its calculation of the allowance for credit losses. The allowance for expected credit losses is based primarily on past collections experience relative to the length of time receivables are past due. However, when available evidence reasonably supports an assumption that future economic conditions will differ from current and historical payment collections, an adjustment is reflected in the allowance for expected credit losses. Accounts receivable are also presented net of an allowance for product returns and trade discounts and allowances because the Company’s customers have the right of setoff for these amounts against the related accounts receivable.

Pre Launch Inventory

Pre-Launch Inventory — An improvement to the manufacturing process for the Company’s primary excipient, fumaryl diketopiperazine (“FDKP”) was demonstrated to be viable and management expects to realize an economic benefit in the future as a result of such process improvement. Accordingly, the Company is required to assess whether to capitalize inventory costs related to such excipient prior to validation of the improved manufacturing process and adoption of the new supplier. In doing so, management must consider a number of factors in order to determine the amount of inventory to be capitalized, including the historical experience of modifying the Company’s manufacturing processes, feedback from technical experts and regulatory agencies on the changes being effected and the amount of inventory that is likely to be used in commercial production. The shelf life of the excipient will be determined as part of the validation process; in the interim, the Company must assess the available stability data to determine whether there is likely to be adequate shelf life to support anticipated future sales occurring beyond the expected adoption date of the new raw material. If management is aware of any specific material risks or contingencies other than the normal regulatory reporting process, or if the criteria for capitalizing inventory produced prior to regulatory approval are otherwise not met, the Company would not capitalize such inventory costs, choosing instead to recognize such costs as R&D expense in the period incurred. See Note 5 – Inventories.

Inventories

Inventories — Inventories are stated at the lower of cost or net realizable value. The Company determines the cost of inventory using the first-in, first-out, or FIFO, method. The Company capitalizes inventory costs associated with the Company’s products based on management’s judgment that future economic benefits are expected to be realized; otherwise, such costs are expensed as incurred as cost of goods sold. The Company uses a contract manufacturing organization outside of the U.S. for certain stages of V-Go inventory.

The Company periodically analyzes its inventory levels to identify inventory that may expire or has a cost basis in excess of its estimated realizable value and writes down such inventories, as appropriate. In addition, the Company’s products are subject to strict quality control and monitoring which the Company performs throughout the manufacturing process. If certain batches or units of product no longer meet quality specifications or may become obsolete or are forecasted to become obsolete due to expiration, the Company will record a charge to write down such unmarketable inventory to its estimated net realizable value. The Company analyzes its inventory levels to identify inventory that may expire or has a cost basis in excess of its estimated realizable value. The Company performs an assessment of projected sales and evaluates the lower of cost or net realizable value and the potential excess inventory on hand at the end of each reporting period.

Property and Equipment

Property and Equipment — Property and equipment is recorded at historical cost, net of accumulated depreciation. Depreciation expense is recorded over the assets’ useful lives on a straight-line basis and included in cost of goods sold, research and development, and general and administrative expense in the condensed consolidated statements of operations. See Note 6 – Property and Equipment.

Impairment of Long-Lived Assets

Impairment of Long-Lived Assets — Long-lived assets include property and equipment, operating lease right-of-use assets and other intangible assets. The Company evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Assets are considered to be impaired if the carrying value is considered to be unrecoverable.

If the Company believes an asset to be impaired, the impairment recognized is the amount by which the carrying value of the asset exceeds the fair value of the asset. Fair value is determined using the market, income or cost approaches as appropriate for the asset. Any write-downs are treated as permanent reductions in the carrying amount of the asset and recognized as an operating loss.

Acquisitions

Acquisitions — The Company first determines whether a set of assets acquired constitute a business and should be accounted for as a business combination. If the assets acquired do not constitute a business, the Company accounts for the transaction as an asset acquisition. Business combinations are accounted for by means of the acquisition method of accounting. Under the acquisition method, assets acquired, including in-process R&D (“IPR&D”), and liabilities assumed are recorded at their respective fair values as of the acquisition date in the Company’s condensed consolidated financial statements. Leases are recorded at the net present value of the remaining lease payments. The excess of the fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill. A gain on bargain purchase is recorded if the fair value of the net assets acquired exceeds the fair value of the

consideration transferred. Contingent consideration obligations incurred in connection with a business combination (including the assumption of an acquiree’s liability arising from an acquisition it consummated prior to the Company’s acquisition) are recorded at their fair values on the acquisition date and remeasured at their fair values each subsequent reporting period until the related contingencies have been resolved. The resulting changes in fair values are recorded in earnings.

In contrast, asset acquisitions are accounted for by using a cost accumulation and allocation model. Under this model, the cost of the acquisition is allocated to the assets acquired and liabilities assumed. IPR&D projects with no alternative future use are recorded in R&D expense upon acquisition, and contingent consideration obligations incurred in connection with an asset acquisition are recorded when it is probable that they will occur and they can be reasonably estimated.

Goodwill and Other Intangible Assets

Goodwill and Other Intangible Assets — The fair value of acquired intangible assets is determined using either a cost approach or an income approach. The cost approach establishes fair value based on the cost of reproducing or replacing the asset, less depreciation for functional or economic obsolescence. The income approach, referred to as the excess earnings method, utilizes Level 3 fair value inputs to determine the present value of future economic benefits to be derived from ownership of the intangible asset. Market participant valuations assume a global view considering all potential jurisdictions and indications based on discounted after-tax cash flow projections, risk adjusted for estimated probability of technical and regulatory success.

The Company tests for impairment annually on a reporting unit basis, at the beginning of the Company’s fourth fiscal quarter and between annual tests if events and circumstances indicate it is more likely than not that the fair value of a reporting unit is less than its carrying amount. To the extent the carrying amount of a reporting unit is less than its estimated fair value, an impairment charge will be recorded.

Finite-lived intangible assets are amortized on a straight-line basis over the estimated useful life. Estimated useful lives are determined considering the period assets are expected to contribute to future cash flows. Finite-lived intangible assets are tested for impairment when facts or circumstances suggest that the carrying value of the asset may not be recoverable. If the carrying value exceeds the projected undiscounted pretax cash flows of the intangible asset, an impairment loss equal to the excess of the carrying value over the estimated fair value (discounted after-tax cash flows) is recognized.

IPR&D acquired in a business combination is considered an indefinite-lived intangible asset until the completion or abandonment of the associated R&D efforts. During the R&D period, the asset is not amortized but rather is tested for impairment when facts or circumstances suggest that the carrying value of the asset may not be recoverable. Once the R&D efforts are completed, the Company accounts for the resulting asset as a finite-lived intangible asset. If the R&D efforts are abandoned, the asset balance is written off to R&D expense.

Recognized Loss on Purchase Commitments

Recognized Loss on Purchase Commitments — The Company reviews the terms of the long-term supply agreements and assesses the need for any accrual for estimated losses, such as lower of cost or net realizable value, that will not be recovered by future product sales. The recognized loss on purchase commitments is reduced as inventory items are received or as the liability is extinguished. See Note 15 – Commitments and Contingencies.

Milestone Rights Liability

Milestone Rights Liability — In July 2013, in conjunction with the execution of a (now repaid) loan agreement with Deerfield Private Design Fund II, L.P. and Deerfield Private Design International II, L.P. (collectively, “Deerfield”), the Company entered into a Milestone Rights Purchase Agreement (the “Milestone Rights Agreement”) pursuant to which the Company issued certain milestone rights to Deerfield Private Design Fund II, L.P. and Horizon Santé FLML SÀRL (the “Original Milestone Purchasers”). The foregoing milestone rights provided the Original Milestone Purchasers certain rights to receive payments of up to $90.0 million upon the occurrence of specified strategic and Afrezza sales milestones, $50.0 million of which remains payable as of September 30, 2024 upon achievement of such milestones (collectively, the “Milestone Rights”). In December 2021, the Milestone Rights were purchased by Barings Global Special Situations Credit Fund 4 (Delaware), L.P. and Barings Global Special Situations Credit 4 (LUX) S.ar.l. (together, the “Milestone Purchasers”). As a result, the Milestone Purchasers have assumed the obligations of the Original Milestone Purchasers and are now entitled to all rights under the Milestone Rights Agreement. The Milestone Rights liability is reported at fair value at the date of the agreement which is periodically offset against payments. See Note 11 – Fair Value of Financial Instruments.

The initial fair value estimate of the Milestone Rights was calculated using the income approach in which the cash flows associated with the specified contractual payments were adjusted for both the expected timing and the probability of achieving the milestones and discounted to present value using a selected market discount rate. The expected timing and probability of achieving the milestones was developed with consideration given to both internal data, such as progress made to date and assessment of criteria required for achievement, and external data, such as market research studies. The discount rate was selected based on an estimation of required rate of returns for similar investment opportunities using available market data. The Milestone Rights liability is remeasured as the specified milestone events are achieved. Specifically, as each milestone event is achieved, the portion of the initially recorded Milestone Rights liability that pertains to the milestone event being achieved, is remeasured to the amount of the specified related milestone payment. The resulting change in the balance of the Milestone Rights liability due to remeasurement is recorded in the

Company’s condensed consolidated statements of operations as interest expense. Furthermore, the Milestone Rights liability is reduced upon the settlement of each milestone payment. As a result, each milestone payment is effectively allocated between a reduction of the recorded Milestone Rights liability and an expense representing a return on a portion of the Milestone Rights liability paid to the investor for the achievement of the related milestone event. See Note 8 – Accrued Expenses and Other Current Liabilities and Note 15 – Commitments and Contingencies.

Fair Value of Financial Instruments

Fair Value of Financial Instruments — The Company applies various valuation approaches in determining the fair value of its financial assets and liabilities within a hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is broken down into three levels based on the source of inputs as follows:

Level 1 — Quoted prices for identical instruments in active markets.

Level 3 — Significant inputs to the valuation model are unobservable.

Income Taxes

Income Taxes — The provisions for federal, foreign, state and local income taxes are calculated on pre-tax income based on current tax law and include the cumulative effect of any changes in tax rates from those used previously in determining deferred tax assets and liabilities. Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. A valuation allowance is recorded to reduce net deferred income tax assets to amounts that are more likely than not to be realized.

For uncertain tax positions, the Company determines whether it is “more likely than not” that a tax position will be sustained upon examination by the appropriate taxing authorities before any part of the benefit can be recorded in the financial statements. For those tax positions where it is “not more likely than not” that a tax benefit will be sustained, no tax benefit is recognized. Penalties, if probable and reasonably estimable, are recognized as a component of income tax expense. The Company has reduced its deferred tax assets for uncertain tax positions but has not recorded liabilities for income tax expense, penalties, or interest.

Contingencies

Contingencies — The Company records a loss contingency for a liability when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. These accruals represent management’s best estimate of probable loss. Disclosure also is provided when it is reasonably possible that a loss will be incurred or when it is reasonably possible that the amount of a loss will exceed the recorded provision. On a quarterly basis, the Company reviews the status of each significant matter and assesses its potential financial exposure. Significant judgment is required in both the determination of probability and the determination as to whether an exposure is reasonably estimable. Because of uncertainties related to these matters, accruals are based only on the best information available at the time. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation and may revise its estimates.

Stock-Based Compensation

Stock-Based Compensation — Share-based payments to employees, including grants of restricted stock units (“RSUs”), performance-based non-qualified stock options awards (“PNQs”), restricted stock units with market conditions (“Market RSUs”), options and the compensatory elements of employee stock purchase plans, are recognized in the condensed consolidated statements of operations based upon the fair value of the awards at the grant date. RSUs are valued based on the market price on the grant date. Market RSUs are valued using a Monte Carlo valuation model and RSUs with performance conditions are evaluated for the probability that the performance conditions will be met and estimates the date at which the performance conditions will be met in order to properly recognize stock-based compensation expense over the requisite service period. The Company uses the Black-Scholes option valuation model to estimate the grant date fair value of employee stock options and the compensatory elements of employee stock purchase plans.

Net Income (Loss) Per Share of Common Stock

Net Income (Loss) Per Share of Common Stock — Basic net income or loss per share ("EPS") is calculated by dividing net income by the weighted average number of common shares outstanding for the period. Diluted EPS reflects the effect of potential common stock issuances resulting from assumed stock option exercises and vesting of restricted stock units, unless the effect is anti-dilutive, when applying the treasury stock method, as well as potential dilution under the if-converted method for convertible debt securities. For periods where the Company has presented a net loss, potentially dilutive securities are excluded from the computation of diluted EPS as they would be anti-dilutive.

Recently Issued Accounting Standards

Recently Issued Accounting Standards — In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures (Topic 740). This ASU requires disaggregated information about a public entity’s effective tax rate reconciliation as well as additional information on income taxes paid. This ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. The Company is currently evaluating the impact of the guidance on its condensed consolidated financial statement disclosures.

From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s condensed consolidated financial position or results of operations upon adoption.

Stock-Based Compensation Expense (Tables)

9 Months Ended

Sep. 30, 2024

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Schedule of Employee Awards and Non-employee Director Award Plan Activity

The Company granted the following awards (in shares):


	Three Months Ended March 31,			Three Months Ended June 30,			Three Months Ended September 30,			Nine Months Ended September 30,
	2024			2024			2024			2024
Employee awards:
RSUs		267,990	(1)		3,205,910	(2)		241,253	(5)		3,715,153
Market RSUs		—			2,144,000	(3)		—			2,144,000
Non-employee director RSUs		—			280,376	(4)		—			280,376
Total awards issued		267,990			5,630,286			241,253			6,139,529

_________________________

(1)

(2)

(3)

(4)

(5)

Stock Based Compensation Expense Recognized in Condensed Consolidated Statements of Operations


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
RSUs and options	$	5,047	$	4,442	$	14,994	$	13,324
Employee stock purchase plan		180		159		546		512
Total	$	5,227	$	4,601	$	15,540	$	13,836

Commitments and Contingencies - Summary of Finance Lease Information (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2024 USD ($)
Commitments And Contingencies Disclosure [Abstract]
Financing lease right-of-use asset	$ 219
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Other Assets Noncurrent
Financing lease liability-current	$ 52
Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Accrued Liabilities Current
Financing lease liability-long-term	$ 171
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Financing lease liability-long-term
Total	$ 223
Weighted average remaining lease term (in years)	4 years 8 months 12 days
Weighted average discount rate	7.25%

Commitments and Contingencies (Tables)

9 Months Ended

Sep. 30, 2024

Commitments And Contingencies [Line Items]

Schedule Of Royalty Liability Account Roll Forward

The following table shows the activity within the Royalty Liability account during the nine months ended September 30, 2024 as well as the effective interest rate (dollars in thousands):


Balance, January 1, 2024	$	145,810
Amortization of deferred transaction costs		172
Non-cash interest expense on liability for sale of future royalties		12,548
Royalty revenue earned by or payable to Sagard		(9,635	)
Balance, September 30, 2024	$	148,895

Effective interest rate	8.8% – 11.5%

Schedule of Lease Term and Discount Rate

Financing liability information was as follows (dollars in thousands):


	September 30, 2024		December 31, 2023
Weighted average remaining lease term (in years)		17.1		17.8

Lease information was as follows (dollars in thousands):


	September 30, 2024			December 31, 2023
Operating lease right-of-use assets(1)	$	13,637		$	4,685

Operating lease liability-current(2)	$	2,431		$	1,423
Operating lease liability-long-term		12,167			3,925
Total	$	14,598		$	5,348

Weighted average remaining lease term (in years)		7.3			3.7
Weighted average discount rate		7.25	%		7.25	%

_________________________

(1)

Operating right-of-use assets related to vehicles, offices and the manufacturing facility for V-Go are included in other assets in the condensed consolidated balance sheets.

(2)

Operating lease liability – current is included in accrued expenses and other current liabilities in the condensed consolidated balance sheets.

Summary of Lease Information


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Interest expense on financing liability	$	2,470	$	2,459	$	7,361	$	7,332


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Operating lease costs	$	719	$	422	$	1,417	$	1,253
Variable lease costs		104		48		122		97
Cash paid		860		268		1,407		825

Summary of Remaining Financing Liability Payments

The Company's remaining financing liability payments were as follows (in thousands):


	September 30, 2024
Remainder of 2024	$	2,532
2025		10,269
2026		10,533
2027		10,849
2028		11,174
Thereafter		177,278
Total		222,635
Interest payments		(116,113	)
Debt issuance costs		(2,519	)
Total financing liability	$	104,003

Summary of Financing Lease Information

Financing lease information was as follows (dollars in thousands):


	September 30, 2024
Financing lease right-of-use asset(1)	$	219

Financing lease liability-current(2)	$	52
Financing lease liability-long-term		171
Total	$	223

Weighted average remaining lease term (in years)		4.7
Weighted average discount rate		7.25	%

_________________________

(1)

Financing right-of-use asset is included in other assets in the condensed consolidated balance sheets.

(2)

Financing lease liability – current is included in accrued expenses and other current liabilities in the condensed consolidated balance sheets.

Remaining Purchase Commitments and Estimated Capacity Fee Liability Requirements

The Company's remaining purchase commitments and estimated capacity fee liability as of September 30, 2024 were as follows (€ in millions):


	September 30, 2024
	Remaining Purchase Commitments		Estimated Capacity Fees
2025		—		1.5
2026(1)		4.2		2.0
2027		6.0		1.0
2028		6.0		1.0
2029		6.0		1.0
2030		6.0		1.0
2031		8.0		0.5
2032		8.0		0.5
2033		8.0		0.5
2034		4.4		0.5
Total		56.6		9.5

_________________________

Schedule of Future Minimum Office And Vehicle Lease Payments

The Company's future minimum office and vehicle lease payments were as follows (in thousands):


	September 30, 2024
Remainder of 2024	$	784
2025		3,157
2026		2,579
2027		2,540
2028		2,087
Thereafter		7,721
Total		18,868
Interest expense		(4,270	)
Total operating lease liability	$	14,598

Audio Visual Equipment

Commitments And Contingencies [Line Items]

Summary of Remaining Financing Liability Payments

The Company's remaining financing lease payments were as follows (in thousands):


	September 30, 2024
Remainder of 2024	$	27
2025		54
2026		54
2027		54
2028		54
Thereafter		23
Total		266
Interest payments		(43	)
Total financing liability	$	223

Subsequent Events (Additional Information) (Details) $ in Millions		1 Months Ended
	Jul. 08, 2024 Employees	Jun. 30, 2024 USD ($)
Subsequent Event [Line Items]
Letters of credit secured by cash held in restricted depository account		$ 0.7
Number of pulmatrix employees which began employment \| Employees	13
Lease term extension period		Effective Date through November 30, 2033
Lease monthly payments		$ 0.1
Percentage of annual increment on lease		3.00%

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Thousands	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ 11,550	$ (2,014)	$ 10,630	$ 1,721	$ (5,265)	$ (9,795)	$ 20,166	$ (13,339)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

Collaboration, Licensing and Other Arrangements - Schedule of Revised Anticipated Cash Flows from Transactions Allocated Performance Obligations (Parenthetical) (Details) - United Therapeutics Corporation - Collaboration and License Agreement
$ in Millions

1 Months Ended

Dec. 31, 2022

USD ($)

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Total anticipated cash flows

$ 722.3

^[1]

Manufacturing Services

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Total anticipated cash flows

722.3

Manufacturing Services and Product Sales

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Allocated transaction price

220.8

Manufacturing Services and Product Sales | Transaction Price For The Contractual Obligations

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Total anticipated cash flows

120.0

Next-Gen R&D Services | Transaction Price For The Performance Obligations

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Total anticipated cash flows

$ 602.3

[1]

Borrowings - Schedule of Line of Credit Facility Debt and Key Terms (Detail) - USD ($) $ / shares in Units, $ in Millions	9 Months Ended
	Sep. 30, 2024	Apr. 02, 2024	Dec. 31, 2023	Mar. 04, 2021
Senior Convertible Notes
Debt Instrument [Line Items]
Amount Due	$ 230.0		$ 230.0
Annual interest rate	2.50%
Maturity date	2026-03
Conversion price	$ 5.21			$ 5.21
MidCap Credit Facility
Debt Instrument [Line Items]
Amount Due			33.3
Maturity date	2025-08
SOFR \| MidCap Credit Facility
Debt Instrument [Line Items]
Annual interest rate	6.25%
Interest rate floor	1.00%
Interest rate cap	8.25%
The Mann Group L L C
Debt Instrument [Line Items]
Conversion price		$ 2.5
The Mann Group L L C \| Convertible Promissory Note
Debt Instrument [Line Items]
Amount Due			$ 8.8
Annual interest rate	2.50%
Maturity date	2025-12
Conversion price	$ 2.5

Commitments and Contingencies - Summary of Lease Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Commitments And Contingencies Disclosure [Abstract]
Operating lease costs	$ 719	$ 422	$ 1,417	$ 1,253
Variable lease costs	104	48	122	97
Cash paid	$ 860	$ 268	$ 1,407	$ 825

Fair Value of Financial Instruments - Fair Value of Financial Instruments (Parenthetical) (Detail) $ in Millions	9 Months Ended	12 Months Ended
	Sep. 30, 2024 USD ($)	Dec. 31, 2023 USD ($)
MidCap Credit Facility
Fair Value Of Financial Instruments [Line Items]
Note payable, percentage of hypothetical yield		12
Note payable, percentage of interest rate increases (decreases)		2.00%
MidCap Credit Facility \| Minimum
Fair Value Of Financial Instruments [Line Items]
Financial liabilities fair value		$ 35.0
MidCap Credit Facility \| Maximum
Fair Value Of Financial Instruments [Line Items]
Financial liabilities fair value		$ 36.0
Mann Group Convertible Notes
Fair Value Of Financial Instruments [Line Items]
Note payable, percentage of hypothetical yield		13.0
Note payable, percentage of interest rate increases (decreases)		2.00%
Mann Group Convertible Notes \| Volatility
Fair Value Of Financial Instruments [Line Items]
Note payable, fair value key inputs		62.7
Mann Group Convertible Notes \| Minimum
Fair Value Of Financial Instruments [Line Items]
Financial liabilities fair value		$ 14.2
Mann Group Convertible Notes \| Maximum
Fair Value Of Financial Instruments [Line Items]
Financial liabilities fair value		$ 14.7
Senior Convertible Notes
Fair Value Of Financial Instruments [Line Items]
Note payable, percentage of hypothetical yield	11	11
Note payable, percentage of interest rate increases (decreases)	2.00%	2.00%
Senior Convertible Notes \| Volatility
Fair Value Of Financial Instruments [Line Items]
Note payable, fair value key inputs	52	62.7
Senior Convertible Notes \| Minimum
Fair Value Of Financial Instruments [Line Items]
Financial liabilities fair value	$ 279.6	$ 224.1
Senior Convertible Notes \| Maximum
Fair Value Of Financial Instruments [Line Items]
Financial liabilities fair value	$ 290.0	$ 238.9
Financing Liability
Fair Value Of Financial Instruments [Line Items]
Note payable, percentage of hypothetical yield	9.5	9.5
Note payable, percentage of interest rate increases (decreases)	2.00%
Financing Liability \| Minimum
Fair Value Of Financial Instruments [Line Items]
Financial liabilities fair value	$ 94.1
Financing Liability \| Maximum
Fair Value Of Financial Instruments [Line Items]
Financial liabilities fair value	$ 121.8
Milestone Rights \| Risk-Free Rate
Fair Value Of Financial Instruments [Line Items]
Note payable, fair value key inputs	3.7	3.9
Milestone Rights \| Dividend Yield
Fair Value Of Financial Instruments [Line Items]
Note payable, fair value key inputs	0	0
Milestone Rights \| Volatility
Fair Value Of Financial Instruments [Line Items]
Note payable, fair value key inputs	50	50
Milestone Rights \| Period
Fair Value Of Financial Instruments [Line Items]
Note payable, fair value key inputs	7.3	8
Milestone Rights \| Credit Risk
Fair Value Of Financial Instruments [Line Items]
Note payable, fair value key inputs	15	17
Contingent Milestone Liability \| Risk-Free Rate
Fair Value Of Financial Instruments [Line Items]
Note payable, fair value key inputs	3.9	4
Contingent Milestone Liability \| Dividend Yield
Fair Value Of Financial Instruments [Line Items]
Note payable, fair value key inputs	0	0
Contingent Milestone Liability \| Volatility
Fair Value Of Financial Instruments [Line Items]
Note payable, fair value key inputs	43	43
Contingent Milestone Liability \| Period
Fair Value Of Financial Instruments [Line Items]
Note payable, fair value key inputs	13.3	15
Contingent Milestone Liability \| Credit Risk
Fair Value Of Financial Instruments [Line Items]
Note payable, fair value key inputs	15	17
Liability for Sale of Future Royalties
Fair Value Of Financial Instruments [Line Items]
Note payable, percentage of hypothetical yield	11
Note payable, percentage of interest rate increases (decreases)	2.00%
Liability for Sale of Future Royalties \| Minimum
Fair Value Of Financial Instruments [Line Items]
Financial liabilities fair value	$ 121.9
Liability for Sale of Future Royalties \| Maximum
Fair Value Of Financial Instruments [Line Items]
Financial liabilities fair value	$ 156.4

Collaboration, Licensing and Other Arrangements - Summary of UT Revenue (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from UT	$ 70,079	$ 51,253	$ 208,728	$ 140,490
United Therapeutics Corporation
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from UT	50,314	33,289	149,346	86,546
United Therapeutics Corporation \| Commercial Supply
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from UT	23,231	12,800	73,673	34,897
United Therapeutics Corporation \| License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from UT		271	347	698
United Therapeutics Corporation \| Royalties Arrangement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from UT	$ 27,083	$ 20,218	$ 75,326	$ 50,951

- Definition

+ References

+ Details

Commitments and Contingencies - Summary of Financing Liability Costs (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Commitments And Contingencies Disclosure [Abstract]
Interest expense on financing liability	$ 2,470	$ 2,459	$ 7,361	$ 7,332

Commitments and Contingencies - Schedule Of Royalty Liability Account Roll Forward (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2024
Commitments And Contingencies [Line Items]
Balance, beginning of period		$ 721,366
Non-cash interest expense on liability for sale of future royalties	$ 4,089	12,720
Balance, end of period	674,126	$ 674,126
Minimum
Commitments And Contingencies [Line Items]
Effective interest rate		8.80%
Maximum
Commitments And Contingencies [Line Items]
Effective interest rate		11.50%
Royalty Liability
Commitments And Contingencies [Line Items]
Balance, beginning of period		$ 145,810
Amortization of deferred transaction costs		172
Non-cash interest expense on liability for sale of future royalties		12,548
Royalty revenue earned by or payable to Sagard		(9,635)
Balance, end of period	$ 148,895	$ 148,895

- Definition

Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-SubTopic 10
-Topic 210
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(24))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(19))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(25))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(26))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(23))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(21))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 25
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481231/810-10-45-25

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (bb)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 15: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-12

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(14))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481404/852-10-50-7

Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481404/852-10-50-7

Reference 29: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Stock-Based Compensation Expense - Schedule of Employee Awards and Non-employee Director Award Plan Activity (Parenthetical) (Details) - $ / shares	3 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024
RSUs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted stock units weighted average grant date fair value	$ 5.3	$ 4.45	$ 3.28
Restricted stock units grant date fair value	219,285	3,033,680	211,895
RSUs \| Share-Based Payment Arrangement, Tranche One
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	33.30%	25.00%	33.30%
Vesting period		4 years	3 years
RSUs \| Share-Based Payment Arrangement, Tranche Two
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	33.30%	33.30%	33.30%
Vesting period		2 years	4 years
RSUs \| Share-Based Payment Arrangement, Tranche Three
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	33.30%	33.30%	33.30%
RSUs \| Share-Based Payment Arrangement, Tranche Four
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		33.30%
Market RSUs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted stock units weighted average grant date fair value		$ 10.3
Employees Awards \| RSUs \| Share-Based Payment Arrangement, Tranche One
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted stock units grant date fair value	21,968	145,980	53,720
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	40.00%
Vesting period	2 years	2 years	2 years
Employees Awards \| RSUs \| Share-Based Payment Arrangement, Tranche Two
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted stock units grant date fair value		26,250	2,375
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	60.00%		25.00%
Vesting period	3 years	3 years	3 years
Employees Awards \| RSUs \| Share-Based Payment Arrangement, Tranche Three
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period	4 years	4 years	4 years
Employees Awards \| Market RSUs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting date		Jul. 15, 2027
Employees Awards \| Market RSUs \| Share-Based Payment Arrangement, Tranche One
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		0.00%
Employees Awards \| Market RSUs \| Share-Based Payment Arrangement, Tranche Two
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		50.00%
Employees Awards \| Market RSUs \| Share-Based Payment Arrangement, Tranche Three
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		100.00%
Employees Awards \| Market RSUs \| Share-Based Payment Arrangement, Tranche Four
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		200.00%
Employees Awards \| Market RSUs \| Index Target 90th Percentile or Higher
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		300.00%
Non-employee Directors Awards \| RSUs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted stock units weighted average grant date fair value		$ 4.45

Income Taxes

9 Months Ended

Sep. 30, 2024

Income Tax Disclosure [Abstract]

Income Taxes

16. Income Taxes

During the three and nine months ended September 30, 2024, the Company recorded income tax expense of $1.3 million and $1.9 million, respectively, related to state taxes, which was calculated using the discrete year-to-date method. The income tax provision for the three and nine months ended September 30, 2023 resulted in no tax expense. The effective tax rate differs from the statutory tax rate of 21% primarily due to the existence of valuation allowances against net deferred tax assets and current liabilities resulting from the estimated state income tax liabilities.

Management of the Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets and concluded, in accordance with the applicable accounting standards, that net deferred tax assets should be fully reserved.

The Company has assessed its position with regards to uncertainty in tax positions and has not recognized a liability for unrecognized tax benefits. The Company does not expect its unrecognized tax benefits to change significantly over the next 12 months. The Company recognizes interest and penalties accrued related to unrecognized tax benefits in income tax expense. During the nine months ended September 30, 2024, the Company did not recognize any interest or penalties. The Company’s tax years since 2019 remain subject to examination by tax authorities.

In June 2024, California enacted Senate Bills 167 and 175 ("SB 167" and "SB 175"). SB 167 suspends the use of net operating losses ("NOLs") and limits the use of business credits to $5.0 million for the 2024-2026 tax years. Under SB 175, the NOL suspension and credit limitations will not apply for the 2025 and 2026 tax years if certain budget goals are met. Although the Company does not expect this legislation to have a material effect on its results of operations or cash flows, management continues to evaluate any potential impact.

- Definition

The entire disclosure for income tax.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477891/740-270-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-13

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/740/tableOfContent

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-14

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-21

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-17

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482603/740-30-50-2

+ Details

Collaboration, Licensing and Other Arrangements - Additional Information (Detail 1) - License and Distribution Agreement - Cipla Ltd - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2018-06-01 $ in Millions	May 31, 2018 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Anticipated revenue allocation	$ 2.2
Deferred revenue recognition period	15 years

Earnings Per Common Share - Components of Basic and Diluted EPS Computations (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
EPS - basic:
Net Income (Loss)	$ 11,550	$ (2,014)	$ 10,630	$ 1,721	$ (5,265)	$ (9,795)	$ 20,166	$ (13,339)
Weighted average common shares (denominator), Basic	274,998			268,732			272,811	266,126
Net income (loss) per share - basic	$ 0.04			$ 0.01			$ 0.07	$ (0.05)
EPS - diluted:
Adjusted net income (loss) (numerator)	$ 11,550			$ 3,578			$ 20,166	$ (13,339)
Weighted average common shares	274,998			268,732			272,811	266,126
Effect of dilutive securities - common shares issuable	9,695			55,038			8,596
Adjusted weighted average common shares (denominator)	284,693			323,770			281,407	266,126
Net income (loss) per share - diluted	$ 0.04			$ 0.01			$ 0.07	$ (0.05)

Collaboration, Licensing and Other Arrangements

9 Months Ended

Sep. 30, 2024

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Collaboration, Licensing and Other Arrangements

10. Collaboration, Licensing and Other Arrangements

Revenue from collaborations and services were as follows (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
UT CSA(1)	$	23,231	$	12,800	$	73,673	$	34,897
UT License Agreement (2)		—		271		347		698
Cipla License and Distribution Agreement		37		37		110		110
Total revenue from collaborations and services	$	23,268	$	13,108	$	74,130	$	35,705

_________________________

(1)

Amounts consist of revenue recognized for Manufacturing Services and Product Sales to UT for the periods presented.

(2)

Amounts consist of revenue recognized for Next-Gen R&D Services and R&D Services and License for the periods presented.

United Therapeutics License Agreement — In September 2018, the Company and UT entered into an exclusive global license and collaboration agreement (the “UT License Agreement”), pursuant to which UT is responsible for global development, regulatory and commercial activities with respect to Tyvaso DPI. Pursuant to the UT License Agreement, the Company receives a 10% royalty on net sales of Tyvaso DPI. In December 2023, the Company sold a 1% royalty on future net sales of Tyvaso DPI to a royalty purchaser, with the Company retaining a 9% royalty. In August 2021, the Company and UT entered into the CSA, pursuant to which the Company is responsible for manufacturing and supplying to UT, and UT is responsible for purchasing from the Company on a cost-plus basis. In addition, UT is responsible for supplying treprostinil at its expense in quantities necessary to enable the Company to manufacture Tyvaso DPI as required by the CSA.

Total revenue from UT was as follows (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
UT Revenue
UT CSA	$	23,231	$	12,800	$	73,673	$	34,897
UT License Agreement		—		271		347		698
Royalties – Collaboration (1)		27,083		20,218		75,326		50,951
Total revenue from UT	$	50,314	$	33,289	$	149,346	$	86,546

_________________________

(1)

The activities and deliverables under the CSA and UT License Agreement resulted in distinct performance obligations which include the: (1) R&D Services and License, (2) Next-Gen R&D Services, and (3) Manufacturing Services and Product Sales.

There have been various amendments to the UT License Agreement and the CSA since inception. As amended, the term of the CSA continues until December 31, 2031 (unless earlier terminated) and is thereafter renewed automatically for additional, successive two-year terms unless (i) UT provides notice to the Company at least 24 months in advance of such renewal that UT does not wish to renew the CSA or (ii) the Company provides notice to UT at least 48 months in advance of such renewal that the Company does not wish to renew the CSA. The Company and UT each have normal and customary termination rights, including termination for material breach that is not cured within a specific timeframe or in the event of liquidation, bankruptcy or insolvency of the other party. The Company accounted for the contract modification as if it were part of the existing contract since the amendment modified the scope and price of the CSA by extending the term and increasing the occupancy rate. The effect of the modification on the transaction price and on the measure of progress is recognized as an adjustment to revenue as of the date of modification. The modification did not result in a change in the activities and deliverables under the CSA.

In December 2022, the Company and UT agreed to fund an additional $39.5 million to support capital and continuous improvement activities and $2.3 million in the development of alternative manufacturing processes. The Company determined that the capital and continuous improvements should be combined with the manufacturing services performance obligation and the alternative manufacturing processes should be combined with the Next-Gen R&D Services. The total revised anticipated cash flows of $722.3 million from the transaction was allocated to the three distinct performance obligations as follows (dollars in millions):

         
        Anticipated

         
        Cash Flow

        Revenue Allocation

        Recognition Method

        Progress Measure

        Revenue
Recognition

Total anticipated cash flow(1)

722.3

        Distinct Performance Obligation

R&D Services and License

—

Over time

Ratably

Aug 2021 - Oct 2021

Next-Gen R&D Services

10.0

Over time

Input

% of completion of costs

Manufacturing Services and
   Product Sales(2)

712.3

Point in time

Transfer of control

__________________________

(1)

(2)

In February 2024, the Company entered into an additional agreement for a separate performance obligation which was accounted for separately as it was distinct from Manufacturing Services and Product Sales and offered at a standalone selling price. Revenue is recognized at a point in time as services are rendered.

As of September 30, 2024, deferred revenue from UT consisted of $70.5 million, of which $6.4 million was classified as current and $64.1 million was classified as long-term on the condensed consolidated balance sheet. As of December 31, 2023, deferred revenue consisted of $77.5 million, of which $8.9 million was classified as current and $68.6 million was classified as long-term on the condensed consolidated balance sheet. The Company determined that the revenue recognition associated with the capital improvements should be combined with the Manufacturing Services and Product Sales performance obligation.

Thirona Collaboration Agreement — In June 2021, the Company and Thirona entered into a collaboration agreement to evaluate the therapeutic potential of Thirona’s compound for the treatment of fibrotic pulmonary diseases. If initial studies are promising, the Company can exercise certain rights to seek a full license to the compound for clinical development and commercialization. The parties will perform their respective obligations and provide reasonable support for research, clinical development and regulatory strategy. The collaboration agreement was accounted for under ASC 808, Collaborative Agreements; however, no consideration was exchanged between the parties. The costs incurred by the Company were expensed as R&D in the condensed consolidated statements of operations. On February 28, 2023, the collaboration agreement was amended to extend the term through June 2024. In accordance

with the amendment, the Company agreed to fund a minimum of $1.1 million to be expended on a revised development plan prepared by Thirona, of which $1.1 million has been funded through September 30, 2024.

Biomm Supply and Distribution Agreement — In May 2017, the Company and Biomm S.A. ("Biomm") entered into a supply and distribution agreement for the commercialization of Afrezza in Brazil. Under this agreement, Biomm was responsible for pursuing regulatory approvals of Afrezza in Brazil, including from the Agência Nacional de Vigilância Sanitária (“ANVISA”) and, with respect to pricing matters, from the Camara de Regulação de Mercado de Medicamentos (“CMED”), both of which were received. Biomm commenced product sales in January 2020. No shipments of product were made to Biomm in 2023 or the first three quarters of 2024.

Cipla License and Distribution Agreement — In May 2018, the Company and Cipla Ltd. (“Cipla”) entered into an exclusive agreement for the marketing and distribution of Afrezza in India and the Company received a $2.2 million nonrefundable license fee. Under the terms of the agreement, Cipla is responsible for obtaining regulatory approvals to distribute Afrezza in India and for all marketing and sales activities of Afrezza in India. The Company is responsible for supplying Afrezza to Cipla. The Company has the potential to receive an additional regulatory milestone payment, minimum purchase commitment revenue and royalties on Afrezza sales in India once cumulative gross sales have reached a specified threshold. Cipla is currently seeking regulatory approval with the India authorities.

The nonrefundable licensing fee was recorded in deferred revenue and is being recognized in net revenue – collaborations over 15 years, representing the estimated period to satisfy the performance obligation. The additional milestone payment represents variable consideration for which the Company has not recognized any revenue because Cipla has not yet obtained all of the required marketing approvals.

As of September 30, 2024, the deferred revenue balance for Cipla was $1.2 million, of which $0.1 million was classified as current and $1.1 million was classified as long term in the condensed consolidated balance sheets. As of December 31, 2023, the deferred revenue balance was $1.4 million, of which $0.2 million was classified as current and $1.2 million was classified as long term in the condensed consolidated balance sheets.

Investments (Tables)

9 Months Ended

Sep. 30, 2024

Schedule Of Investments [Abstract]

Schedule of Contractual Maturities of Held to Maturity Investments

The contractual maturities of the Company’s held-to-maturity investments are summarized below (in thousands):


	September 30, 2024				December 31, 2023
	Amortized Cost Basis		Aggregate Fair Value		Amortized Cost Basis		Aggregate Fair Value
Due in one year or less(1)	$	230,797	$	231,555	$	115,263	$	115,374
Due after one year through five years		16,796		16,992		7,155		7,197
Total	$	247,593	$	248,547	$	122,418	$	122,571

___________________________

(1)

The investments due in one year or less include cash equivalents of $41.6 million as of September 30, 2024 and $58.6 million as of December 31, 2023.

Schedule of Fair Value of Cash Equivalents, Long and Short Term Investments

The fair value of the cash equivalents, long-term and short-term investments are disclosed below (dollars in thousands).


	September 30, 2024
	Investment Level	Amortized Cost (Carrying Value)			Gross Unrealized Holding Gains		Gross Unrealized Holding Losses			Estimated Fair Value
Money market funds and other	Level 1	$	31,298		$	—	$	—		$	31,298
Commercial bonds and paper	Level 2		57,477			268		(12	)		57,733
U.S. Treasury Securities	Level 2		158,818			700		(2	)		159,516
Total cash equivalents and investments			247,593			968		(14	)		248,547
Less: cash equivalents			(41,582	)		—		—			(41,582	)
Total Investments		$	206,011		$	968	$	(14	)	$	206,965


	December 31, 2023
	Investment Level	Amortized Cost (Carrying Value)			Gross Unrealized Holding Gains		Gross Unrealized Holding Losses			Estimated Fair Value
Money market funds	Level 1	$	69,611		$	—	$	—		$	69,611
Commercial bonds and paper	Level 2		43,251			135		(38	)		43,348
U.S. Treasury Securities	Level 2		9,556			56		—			9,612
Total cash equivalents and investments			122,418			191		(38	)		122,571
Less: cash equivalents			(58,644	)		—		—			(58,644	)
Total Investments		$	63,774		$	191	$	(38	)	$	63,927

- Definition

Tabular disclosure of information about investment in debt security measured at amortized cost (held-to-maturity).

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5B

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (aaa)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (f)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (f)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (f)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (f)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5A

Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5A
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5A

Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5A
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5A

Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5B

Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5B
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5B

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5B
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5B

Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-5B

+ Details

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2024	Dec. 31, 2023
Statement Of Financial Position [Abstract]
Undesignated preferred stock, par value	$ 0.01	$ 0.01
Undesignated preferred stock, shares authorized	10,000,000	10,000,000
Undesignated preferred stock, shares issued	0	0
Undesignated preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	800,000,000	800,000,000
Common stock, shares issued	275,775,038	270,034,495
Common stock, shares outstanding	275,775,038	270,034,495

Description of Business and Significant Accounting Policies

9 Months Ended

Sep. 30, 2024

Accounting Policies [Abstract]

Description of Business and Significant Accounting Policies

1. Description of Business and Significant Accounting Policies

The unaudited condensed consolidated financial statements of MannKind Corporation and its subsidiaries (“MannKind,” the “Company,” “we” or “us”), have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (the “SEC”). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The information included in this quarterly report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on February 27, 2024 (the “Annual Report”).

In the opinion of management, all adjustments, consisting only of normal, recurring adjustments, considered necessary for a fair presentation of the results of these interim periods have been included. The results of operations for the three and nine months ended September 30, 2024 may not be indicative of the results that may be expected for the full year.

Financial Statement Estimates — The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and notes. Actual results could differ from those estimates or assumptions. Management considers many factors in selecting appropriate financial accounting policies and in developing the estimates and assumptions that are used in the preparation of the financial statements. Management must apply significant judgment in this process. These effects could have a material impact on the estimates and assumptions used in the preparation of the condensed consolidated financial statements. The more significant estimates include revenue recognition, including gross-to-net adjustments, stand-alone selling price considerations for recognition of collaboration revenue, assessing long-lived assets for impairment, clinical trial expenses, inventory costing, stock-based compensation, the determination of the provision for income taxes and corresponding deferred tax assets and liabilities, the valuation allowance recorded against net deferred tax assets, and expected cash flows from royalties received in connection with United Therapeutics' ("UT's") net revenue for the sale of Tyvaso DPI.

Basis of Presentation — The condensed consolidated financial statements have been prepared in accordance with GAAP.


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Net revenue:
Product revenue (1)	$	42,959	$	30,727	$	132,945	$	88,731
Services (2)		37		308		457		808
Royalties (3)		27,083		20,218		75,326		50,951
Total net revenue	$	70,079	$	51,253	$	208,728	$	140,490

_________________________

(1)

Amounts represent the revenue from Afrezza and V-Go sales to wholesalers and specialty pharmacies and Tyvaso DPI to UT.

(2)

(3)

Amounts represent royalties on UT’s net revenue from Tyvaso DPI sales.


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Cost of goods sold and cost of revenue:
Product revenue	$	18,023	$	13,983	$	56,651	$	44,006
Services		—		271		347		698
Total cost of goods sold and cost of revenue	$	18,023	$	14,254	$	56,998	$	44,704

Level 1 — Quoted prices for identical instruments in active markets.

Level 3 — Significant inputs to the valuation model are unobservable.

Accrued Expenses and Other Current Liabilities

9 Months Ended

Sep. 30, 2024

Payables And Accruals [Abstract]

Accrued Expenses and Other Current Liabilities

8. Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities were comprised of the following (in thousands):


	September 30, 2024		December 31, 2023
Salary and related expenses	$	16,239	$	19,506
Discounts and allowances for commercial product sales		9,869		9,541
Accrued interest		479		2,153
Deferred lease liability		2,483		1,423
Current portion of milestone rights liability(1)		639		752
Returns reserve for acquired product(2)		1,468		601
Professional fees		563		979
State income tax liability		1,507		1,561
Other		4,139		5,520
Accrued expenses and other current liabilities	$	37,386	$	42,036

_________________________

(1)

See Note 15 – Commitments and Contingencies under Contingencies — Milestone Rights.

(2)

See Note 15 – Commitments and Contingencies under Loss Contingencies — Returns Reserve for Acquired Product.

Pulmatrix Transaction

9 Months Ended

Sep. 30, 2024

Business Combination And Asset Acquisition [Abstract]

Pulmatrix Transaction

2. Pulmatrix Transaction

On May 28, 2024, the Company executed a bill of sale and assignment agreement with Pulmatrix, Inc. ("Pulmatrix") whereby the Company acquired from Pulmatrix certain lab assets and assumed certain liabilities, including the lease for an R&D facility in Bedford, Massachusetts. Concurrently, the Company and Pulmatrix entered into an intellectual property cross-license agreement (the "Cross License Agreement") for the Company's out-licensing of its Cricket® Device to Pulmatrix and in-licensing of Pulmatrix's iSPERSE™ technology, and a master service agreement. The parties and landlord also entered into an amendment to lease and consent to assignment of the lease. Each of these agreements became effective upon the closing of the collective transaction (the "Pulmatrix Transaction") on July 8, 2024 (the "Effective Date"). The Company also entered into employment agreements with 13 Pulmatrix R&D employees who began employment with the Company on the Effective Date.

Pursuant to the Cross License Agreement, the Company granted to Pulmatrix certain exclusive and non-exclusive rights to develop, use, manufacture, market, offer and sell its single-use disposable dry powder inhaler (the "Cricket Device") for the inhaled delivery of dihydroergotamine in any formulation whatsoever (including Pulmatrix's’s PUR3100 treatment of acute migraine), and the inhaled delivery of one or more active pharmaceutical ingredients formulated with iSPERSE for the treatment of neurological disease in humans (collectively, the “Cricket License”).

In return, Pulmatrix granted to the Company certain exclusive and non-exclusive rights to develop, use, manufacture, market, offer and sell iSPERSE formulations of clofazimine and insulin, and formulations of iSPERSE with one or more active pharmaceutical ingredients for the treatment of nontuberculous mycobacteria lung disease in humans, endocrine disease in humans, and interstitial lung diseases in humans (collectively, the “iSPERSE License”).

The Company may also provide certain development services to Pulmatrix under the Master Services Agreement, including but not limited to, activities to develop a dry powder formulation of the active pharmaceutical ingredient that Pulmatrix provides to the Company for oral inhalation using iSPERSE.

Accounting Treatment

The Pulmatrix Transaction was accounted for as a business combination using the acquisition method of accounting, which requires, among other things, the assets acquired and liabilities assumed to be recognized at their respective fair values as of the Effective Date. The excess of the fair value of the net assets acquired over the purchase price in this non-cash transaction was recorded as a gain on bargain purchase.

The fair values of identifiable assets acquired and liabilities assumed by the Company from Pulmatrix as of the Effective Date are reflected below (in thousands):


	Amount
Assets:
iSPERSE License – IPR&D	$	4,300
Right-of-use asset – Bedford R&D facility		10,057
Property and equipment		959
Total assets		15,316
Liabilities:
Operating lease liability – Bedford R&D facility		10,057
Total liabilities		10,057
Net assets acquired – Gain on bargain purchase	$	5,259

The fair value of the Cricket License transferred to Pulmatrix was determined to be immaterial based on the current market availability of numerous third party single-dose dry powder inhalers and the significant time, cost, and risk required to potentially commercialize the Cricket Device. The transfer of the Cricket License was within the scope of ASC 606 as a sale of functional intellectual property, however, since no value was attributed to the Cricket License, no revenue was recognized by the Company.

The fair value of the iSPERSE License was determined by applying a cost approach, which assesses current replacement cost to acquire or construct a substitute asset of comparable utility as of the Effective Date. The iSPERSE License was deemed to have a fair value of $4.3 million based on the estimate of internal and external costs to recreate the underlying technology, which are inputs not observable in the market and therefore considered Level 3 measurements. The iSPERSE technology will be utilized in the Company's continuing R&D efforts and accounted for as IPR&D.

The fair values of the right-of-use asset and lease liability for the assumed R&D facility operating lease were assessed in accordance with ASC 842, Leases, based on discounted cash flows from future lease payments, utilizing the Company’s incremental borrowing rate of 7.25%. In June 2024, in anticipation of the facility lease assumption on the Effective Date, the Company transferred $0.7 million to a depository account at a financial institution to collateralize a conditional stand-by letter of credit as required under the lease. This amount is reflected as long-term restricted cash as of September 30, 2024. The lease term extends from the Effective Date through November 30, 2033 with monthly payments of $0.1 million increasing 3% annually starting on December 1, 2024. See Note 15 – Commitments and Contingencies.

Property and equipment were assessed for monetary benefit, remaining economic life, and relative risk based on the Company's industry knowledge and analysis of sales of comparable equipment to arrive at fair value.

Transaction costs totaling $0.1 million were expensed as incurred and reflected in the condensed consolidated statements of operations for the three and nine months ended September 30, 2024.

Pro forma results of operation for the Transaction have not been presented, as the effects of the Transaction were not material to the condensed consolidated financial statements.

Commitments and Contingencies - Remaining Purchase Commitments and Estimated Capacity Fee Liability Requirements (Detail) € in Millions	Sep. 30, 2024 EUR (€)
Purchase Obligation Fiscal Year Maturity [Abstract]
Remaining Purchase Commitments, 2026	€ 4.2
Remaining Purchase Commitments, 2027	6.0
Remaining Purchase Commitments, 2028	6.0
Remaining Purchase Commitments, 2029	6.0
Remaining Purchase Commitments, 2030	6.0
Remaining Purchase Commitments, 2031	8.0
Remaining Purchase Commitments, 2032	8.0
Remaining Purchase Commitments, 2033	8.0
Remaining Purchase Commitments, 2034	4.4
Remaining Purchase Commitments, Total	56.6
Estimated Capacity Fees, 2025	1.5
Estimated Capacity Fees, 2026	2.0
Estimated Capacity Fees, 2027	1.0
Estimated Capacity Fees, 2028	1.0
Estimated Capacity Fees, 2029	1.0
Estimated Capacity Fees, 2030	1.0
Estimated Capacity Fees, 2031	0.5
Estimated Capacity Fees, 2032	0.5
Estimated Capacity Fees, 2033	0.5
Estimated Capacity Fees, 2034	0.5
Estimated Capacity Fees, Total	€ 9.5